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Simple Summary: Cancer stem cells (CSCs) represent a distinct cancer subpopulation that can
influence the tumour microenvironment, in addition to cancer progression and relapse. A multitude
of factors including CSC properties, long noncoding RNAs (lncRNAs), and autophagy play pivotal
roles in maintaining CSCs. We discuss the methods of detection of CSCs and how our knowledge of
regulatory and cellular processes, and their interaction with the microenvironment, may lead to more
effective targeting of these cells. Autophagy and lncRNAs can regulate several cellular functions,
thereby promoting stemness factors and CSC properties, hence understanding this triangle and its
associated signalling networks can lead to enhanced therapy response, while paving the way for the
development of novel therapeutic approaches.
Abstract: Cancer stem cells (CSCs) possess properties such as self-renewal, resistance to apoptotic
cues, quiescence, and DNA-damage repair capacity. Moreover, CSCs strongly influence the tumour
microenvironment (TME) and may account for cancer progression, recurrence, and relapse. CSCs
represent a distinct subpopulation in tumours and the detection, characterisation, and understanding
of the regulatory landscape and cellular processes that govern their maintenance may pave the
way to improving prognosis, selective targeted therapy, and therapy outcomes. In this review,
we have discussed the characteristics of CSCs identified in various cancer types and the role of
autophagy and long noncoding RNAs (lncRNAs) in maintaining the homeostasis of CSCs. Further,
we have discussed methods to detect CSCs and strategies for treatment and relapse, taking into
account the requirement to inhibit CSC growth and survival within the complex backdrop of cellular
processes, microenvironmental interactions, and regulatory networks associated with cancer. Finally,
we critique the computationally reinforced triangle of factors inclusive of CSC properties, the process
of autophagy, and lncRNA and their associated networks with respect to hypoxia, epithelial-to-
mesenchymal transition (EMT), and signalling pathways.
Keywords: cancer stem cells (CSCs); tumour microenvironment; solid cancers; haematological
malignancies; autophagy; LncRNAs
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1. Introduction
The process of cellular transformation resulting from the accumulation of mutations
and outgrowth of cells in an evolutionary manner, according to fitness, is a central dogma
of cancer biology. This stochastic process has been employed to explain intra- and inter-
tumour heterogeneity. However, a second model exists whereby cancer stem cells (CSCs)
represent the apex of a hierarchy from which progeny differentiate that then constitute
the majority of the tumour mass. The two models are not necessarily mutually exclusive
and may cooperate whereby CSCs may also evolve stochastically producing genetically
diverse offspring [1]. Indeed, the stochastic clonal evolution model posits that tumour
cells possess similar growth potential and through selective pressure, some sub-clones
may become dominant constituting the majority of the tumour and further promoting
growth [2,3]. Mounting evidence in the field of cancer biology suggests that CSCs exist
in a variety of malignancies although with some caveats [4]. The CSC model states that
not all cells of the tumour population possess similar potential, rather populations of cells
can initiate tumours and possess properties such as quiescence and unlimited proliferative
capacity [5,6]. Analogous to normal tissue ontogeny and stem cell development, CSCs
in this model are proposed to be organised in a hierarchical manner [5]. Based on this
model, CSCs sit at the top of the hierarchical order within the tumour cell population
and govern tumour progression. In addition to unlimited proliferative capacity, CSCs can
sustain tumour growth and maintenance and have been shown to form tumours in non-
obese diabetic/severe combined immunodeficient (NOD/SCID) mice [5,7]. The process of
self-renewal in CSCs, similar to stem cells, may be influenced by the microenvironment
of the tumour and external factors, and hence they are not self-autonomous units [8].
Furthermore, CSCs express cellular efflux pumps, anti-apoptotic proteins, and have low
levels of reactive oxygen species (ROS) [9]. Despite progress made in the field of cancer
biology, the CSC model is still currently a subject of much debate. Nonetheless, in practical
terms, cancer growth promotion, aggressive behaviour, and metastasis depend on the
presence of these cells in cancers [10,11].
With respect to the origin of CSCs, they may originate from transformed tissue-specific
stem cells [12,13]. However, it is also possible that CSCs arise from mutant progenitor cells
that have acquired stem-like properties in response to the acquisition of certain genomic
alterations [14]. CSCs were first identified in haematological malignancies and some solid
cancers, and were thought to account for recurrence, metastasis, drug and radiotherapy
resistance [15–17]. If the consensus definition of a CSC is a cell with self-renewal capacity
that can give rise to a heterogeneous population within the tumour [14], then naturally
this definition can encapsulate several cell populations. In many cases, the term CSC is
used interchangeably with cancer-initiating cells and tumour-propagating cells. However,
cancer-initiating cells are perhaps more representative of the cell of origin rather than
the cell that exists in the established malignancy and drives tumour growth. Likewise,
CSCs need not necessarily be transformed tissue-specific stem cells in which case, tumour-
propagating cells are maybe more representative of the tumour cell population under
discussion in this review (Figure 1). Another terminology that is commonly used is that of
cancer persister cells which are a fraction of the tumour population that escape therapy
and may remain dormant in niches, hence not being eliminated by immune surveillance or
cancer therapy [18]. As such, drug resistance may be due to persister cells that manipulate
their microenvironment and may undergo genetic and epigenetic changes that lead to drug
resistance [19]. In this review, we will use the term CSC to describe the population of cells
that drives tumour growth in the established malignancy and gives rise to the bulk tumour
mass [20]. In experimental terms, this population is represented by the cells that generate a
tumour that fully phenocopies the primary tumour by serial xenotransplantation through
immunocompromised mice or via sphere-forming assays in vitro [5]. In essence, CSCs,
like tissue-specific stem cells, are considered relatively quiescent, represent the minority
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of the tumour mass, can self-renew, and give rise to progeny. However, the notion that
CSCs constitute a minor population was challenged by a study of melanoma in which
approximately 25% of unselected cells from primary and metastatic melanomas formed
tumours in immunodeficient mouse models [21,22]. Moreover, accumulating evidence
implicates long noncoding RNAs (lncRNAs) in regulating key aspects of CSC properties
such as the maintenance of stemness, self-renewal, and tumour progression [23–25]. For
instance, H19 is involved in tumourigenesis and cancer progression in both haematological
and solid cancers [26]. Further, pro-survival cellular processes such as autophagy, triggered
chiefly by hypoxia, can be exploited by CSCs to sustain their survival [27]. In this review, we
describe methods that have been used to identify CSCs and consider defining characteristics
of CSCs in both solid and haematological cancers. Furthermore, we have sought evidence
pertaining to the contribution of lncRNAs and autophagy in the maintenance of CSCs and
how these regulatory factors and microenvironmental processes can affect outcomes of
cancer therapy. We provide an appraisal of a computationally reinforced triangle inclusive
of CSC properties, autophagy, and lncRNA and their associated networks with respect to
hypoxia, epithelial-to-mesenchymal transition (EMT), and signalling pathways.
Figure 1. The distinction between cancer stem cells (CSCs) and cancer-initiating cells. A cancer-initiating cell (in blue)
undergoes oncogenic transformation in order to develop a tumour, while a cancer stem cell (CSC, in dark purple) is not
necessarily the transformed tissue-specific stem cell, but rather gives rise to the bulk of the tumour.
2. Methods for Detecting and Understanding the Characteristics of CSCs
If we concede that CSCs share qualities of tissue-specific stem cells, then it would be
logical to test definitive markers and properties of these cells to identify CSCs. Indeed, one
of the most widely used methods of detection and isolation of CSCs in cancers is by the
detection of a cell surface expression profile reflective of the respective tissue-specific stem
cell. Proteins such as CD44, CD90, and CD133 are regarded as common stem cell markers
and are frequently employed to isolate CSCs in various cancer types (Table 1).
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Table 1. Examples of surface markers, stemness proteins, or factors that support the maintenance of
stemness across multiple cancer types.
Cancer Type
Examples of Surface Markers, Stemness
Proteins, or Factors Supporting the Maintenance
of Stemness
AML CD34+ CD38- or CD34- cells [17,28–30]
Oesophageal cancer B7H4, LETM1, CD90 [31,32]
Colorectal cancer CD44, CD133, ST6GALNAC1 [33]
Gastric cancer CD44, SOX2, KLF4, and OCT4 [34,35]
Pancreatic cancer CD133, CD24, CD44, ESA [36,37]
Liver cancer (hepatocellular carcinoma) CD13, CD24, CD44, CD90, CD133 and EpCAM[38]
Lung Cancer (Non-small cell lung cancer) SOX2 and NANOG [39]CDKN1A, SNAI1, and ITGA6 [40]
Glioblastoma multiforme CD133 [41]SOX2, OCT4, NANOG, and SALL4 [42]
Osteosarcoma SOX2 [43]
Breast cancer CD44+ CD24-/low ALDH1+ [13,44]
CSCs may also be characterised by their ability to efflux compounds, such as dyes,
via ATP-binding cassette (ABC) transporters including MDR1/ABCB1 [45]. To that end,
side population (SP) analysis was initially developed to enrich for haemopoietic stem cells
in murine bone marrow and are detected by flow cytometry for quiescent cells that efflux
Hoechst 33342 dye, with the non-stem cell population fluorescing post-excitation of the
retained dye by UV light. This subpopulation within tumours may contain cells with
stem-like characteristics [46]. This shows that SP analysis can enrich for a cell population
with CSC properties although the SP may not exclusively contain CSCs. Another method
to detect CSCs is the aldefluor assay which exploits the unique property of stem cells
whereby high levels of aldehyde dehydrogenase 1 (ALDH1) activity are associated with
stem-like properties. This enzyme is involved in the detoxification of aldehydes and
retinoic acid synthesis, and may also contribute to the regulation of CSC self-renewal and
differentiation, preventing damage from ROS and ultimately inhibiting apoptosis [47,48].
CSCs can also be detected by their ability to form tumours both in vitro and in vivo.
Methods for addressing self-renewal and differentiation include sphere-forming and serial
colony-formation assays showing not only anchorage-independent growth but also self-
renewal capacity [49]. In addition, distinct characteristics of tissue-specific stem cells such
as quiescence and dormancy have been applied to their identification, processes that can
be regulated by changes to the epigenetic landscape, increased methylation of histones,
and the formation of heterochromatin [50]. However, the caveat of simplistic 2D models
is that they cannot effectively emulate the complexity of the tumour microenvironment
(TME), and factors such as cell–cell and cell–matrix interactions, as well as a realistic
distribution of oxygen, nutrients, or signalling proteins [51]. A popular assay that accounts
for these factors is the multicellular tumour spheroid (MTS) method that bridges the gap
between monolayer 2D cultures and in vivo models [52]. Finally, serial transplantation
experiments whereby limiting dilutions of human tumour cells are propagated through
immunodeficient mice can indicate the frequency of the CSC population. Furthermore,
defined subpopulations of tumour cells can be propagated through immunodeficient
mouse models (e.g., NOD/SCID) to assess them not only for self-renewal capabilities
but also for their regenerative potential in turn producing a malignancy with the same
cellular and molecular heterogeneity of the parent tumour [53]. CSCs can divide both
symmetrically and asymmetrically in the xenografted immunodeficient mouse model,
through which the new CSCs and daughter cells are produced [54]. However, one caveat is
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that the complex immune profiles of these models might underestimate the frequency of
CSCs and lead to their misidentification. Overall, serial transplantation, cell surface protein
expression, and in vitro assays, are collectively required to rigorously examine potential
CSCs for stem-like properties.
3. Identification of Cancer Stem Cells in an Array of Cancers
In this section, we present evidence supporting the existence of CSCs and their charac-
teristics across ten malignancies.
3.1. Acute Myeloid Leukaemia (AML)
Evidence supporting the existence of CSCs was first revealed in AML. Bonnet and
Dick demonstrated heterogeneity in cancer cell populations in AML and furthermore that
distinct cells within the leukaemic clone could give rise to AML in the NOD/SCID mouse
xenograft model [17]. Subsequently, these cells were termed SCID leukaemia-initiating
cells (SL-ICs) [17]. These SL-ICs were shown to exclusively express a CD34++CD38-
surface profile similar to haemopoietic stem cells [17,28,29], although these data have since
been disputed [30]. Overall, it is possible to conclude that despite the identification of
subpopulations within the AML tumours with self-renewal capacity, universal markers of
leukaemia stem cells (LSCs) remain inconclusive.
3.2. Oesophageal Cancer
Several proteins including CD44, MAML1, CD271, and CD90 have been proposed
to identify CSCs in osophageal squamous cell cancer (ESCC) as has Hoechst 3342 dye
efflux, in vitro colony formation assays, and xenotransplantation [55]. In particular, CD90+
oesophageal CSCs, isolated from primary tissue, were linked to the promotion of metastasis
by deregulating ETS-1/MMP signalling pathways [56]. Other properties of oesophageal
CSCs were reported as the ability to form spheres in vitro, possessing ALDH1 activity,
and having distinct glycolysis and oxidative phosphorylation activities. These CSCs also
displayed a dependence on signalling pathways such as the Hsp27-AKT-HK2 pathway [57].
In a follow-up study, B7H4 was identified as a novel marker of oesophageal CSCs that
express SOX9 and OCT4 [31]. This group also showed that LETM1 may be a marker
of CSCs in this cancer; expression of this protein positively correlated with that of the
stemness marker OCT4 as well as cyclin D1, and was associated with hypoxia-inducible
factor 1 alpha (HIF-1a) expression [32].
3.3. Colorectal Cancer
Colorectal cancer CSCs have been independently identified as cells in the bulk tumour
expressing the specific markers CD133 and CD44, by sphere formation, ALDH1 activity,
and the presence of SPs [58–60].
These cells expressed higher levels of ST6GALNAC1 had increased sphere-forming
capacity and were resistant to therapy. From a mechanistic viewpoint, the group revealed
that the role of ST6GALNAC1 in maintaining colorectal CSCs was modulated through the
PI3-Kinase/AKT pathway [33].
3.4. Gastric Cancer
Gastric cancer CSCs were isolated from cell lines such as the SGC7901 cell line by
pre-treatment with vincristine, thereby eliminating the non-CSC and enriching for the
drug efflux pump-expressing, multidrug resistant CSCs [34]. Furthermore, the surviving
non-CSC upregulated expression of OCT4, OCT4a, and SOX2, essentially dedifferentiating
into stem-like cells [34]. Moreover, these cells expressed mesenchymal markers such as
SNAIL, TWIST, and vimentin, and low levels of E-cadherin, while demonstrating an ability
to form gastric crypt-like structures marked by expression of gastrointestinal genes such as
CDX2 and SOX2 [34]. Finally, these CSCs displayed a marked capacity for tumourigenesis
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in vivo undergoing both symmetric and asymmetric division [34]. Other markers of CSCs
in this cancer include CD44 and KLF4 [34,35].
3.5. Pancreatic Cancer
The identity of pancreatic adenocarcinoma CSCs was reported by Li and colleagues [36].
This group used xenotransplantation to identify a tumourigenic sub-population of cancer
cells isolated from human primary pancreatic cancer tissue expressing CD44, CD24, and
epithelial-specific antigen (ESA) [36]. This group reported that just 100 CD44+CD24+ESA+
cells were sufficient to faithfully capture the full characteristics of the primary human
tumour in an orthotopic mouse xenograft model [36]. Furthermore, pancreatic CSCs ex-
pressing CD133 displayed tumourgenic properties and were resistant to chemotherapy
(although these cells may represent persister cell populations rather than CSCs) [37].
3.6. Hepatocellular Carcinoma
Hepatocellular CSCs have been defined by the expression of cell surface proteins
including CD13, CD24, CD44, CD90, CD133, and EpCAM [38]. Moreover, ALDH1 activity
and Hoechst dye efflux are among other characteristics of these cells, while xenotransplan-
tation has been used to rigorously test self-renewal capacity [38].
3.7. Lung Cancer
CSCs of lung adenocarcinoma were identified by ALDH1 expression levels whereby
ALDH1-high populations isolated from primary tissue, expressing SOX2 and NANOG,
produced spheroids in culture [39]. Furthermore, CSCs isolated from NSCLC primary
tissue showed unlimited growth capacity and self-renewal properties producing spheroids
in vitro and tumours in vivo [40]. These CSCs were distinguished within tumourspheres as
cells expressing NANOG, CD44, ITGA6, SNAI1, NOTCH3, and CDKN1A [40]. Moreover,
CDKN1A, SNAI1, and ITGA6 expression levels were determined to be of prognostic value
for patients and were utilised to determine a so-called “CSC score” [40].
3.8. Glioblastoma Multiforme
Cells expressing proteins including SOX2, OCT4, pSTAT3, KLF4, NANOG, and SALL4
were identified as CSCs in Glioblastoma multiforme (GBM) [42]. From a functional view-
point, studies have shown the capacity of GBM CSCs (CD133+) isolated from primary
tissue to form spheroids in culture [61]. Moreover, CD133, a protein also expressed by
neural stem cells, further defines CSC in primary human GBM, as they generate tumours
in NOD/SCID mice [62]. However, CD133 cells isolated from primary patient tissue have
been shown to generate tumours on implantation into rat brains also giving rise to CD133+
cells [41]. Other proteins such as CD44 and KLRC3 have also been investigated as mark-
ers of a CSC population, although recent evidence suggests that CD44 is an unreliable
marker; cells expressing low levels of CD44 isolated from patient samples, also display
CSC characteristics [42,63,64].
3.9. Osteosarcoma
Human osteosarcoma primary tissue has been shown to contain SPs detected follow-
ing Hoechst 33342 dye efflux. These SPs form colonies and self-renew both in vitro and
in vivo in xenotransplantation experiments [46]. These SPs were further characterised as
expressing ATP-binding cassette protein transporters and the stemness marker OCT4 [65].
Another protein associated with a CSC phenotype in osteosarcoma is SOX2 which was
shown to maintain this cell population via modulation of the Hippo pathway [43]. In
evidence, conditional knockout of SOX2 in a mouse model of osteosarcoma resulted in a
dramatic reduction in tumour development supporting the role of this stemness gene in
maintaining tumour growth and providing evidence towards a population of cells with
stem-like features in osteosarcoma [66].
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3.10. Breast Cancer
The tumourigenic properties of breast cancer have been attributed to a population of
CD44+CD24-/low cells (accounting for 11–35% of the bulk tumour), isolated from primary
tumour tissue, that give rise to malignancies in xenograft models, following orthotopic
transplantation into the mammary fat pad of NOD/SCID mice [13]. This cell phenotype has
been further refined whereby CD44+CD24-/low cells expressing active ALDH1, enriched
following doxorubicin treatment, were able to reproduce the bulk tumour in a mouse
xenograft model [13,44].
4. Autophagy and CSCs
4.1. Autophagy: A Cellular Pro-Survival Process
Macroautophagy, hereafter called autophagy, is a catabolic cellular process by which
cellular material is degraded. Derived from the Greek words auto, meaning “self” and
phagein, “to eat”, autophagy is important in the maintenance of cellular homeostasis in
eukaryotic systems [67]. It is one of two main routes by which proteins are degraded
within the cell, the other being the ubiquitin proteasome system (UPS). The UPS deals
with the rapid removal of short-lived proteins whereas autophagy concerns long-lived
proteins, organelles, and non-protein targets (such as lipids and carbohydrates) [68]. The
UPS consumes ATP in the degradation process while autophagy generates energy from
the degradation of macromolecules [69]. The generation of energy through autophagy is
important in the maintenance of cellular homeostasis.
Autophagy occurs constitutively at basal levels in nutrient-rich, healthy cells, and is
stimulated when cells are exposed to stressors such as nutrient starvation, mitochondrial
depolarisation, toxic protein aggregates, infection, and mechanical damage [70]. Depending
on the nature and duration of the stress and the cell type, cells can display either protective
or destructive autophagic responses. The initial response of a cell to a stressful stimulus is
often the promotion of pro-survival actions. If these are unsuccessful, destructive pathways
such as apoptosis, necrosis, and pyroptosis are activated, which eliminate these damaged
cells [71]. Autophagy is largely regarded as a pro-survival process, although it can lead to
cellular demise.
The process of autophagy involves the formation of a double membraned vesicle called
an autophagosome, which encapsulates cellular components earmarked for degradation
(Figure 2A) [72–74]. This process is modulated by a family of proteins termed “autophagy-
related” (Atg) proteins. Autophagy induction takes place when signalling pathways trigger
the formation of a membrane invagination described as an omegasome, mainly observed on
the surface of the ER. However, other membranes such as the plasma membrane have been
shown to act as sites of initiation [75]. This structure enlarges into a phagophore (either
independently of, or associated with, the ER) and targets cellular material in close proximity
for digestion. The phagophore elongates and eventually forms the autophagosome [76].
The mature autophagosome then becomes acidified following fusion with a lysosome
in a Ca2+ -dependent manner to produce autophagosome [77]. This fusion unites the
degradative acid hydrolases with the captured cell material. Following the breakdown of
the cellular material, nutrients such as amino acids and fatty acids are exported back into
the cytoplasm by lysosomal permeases [78]. As with other intracellular trafficking events,
autophagosomes move through cytoskeleton-dependent action. This movement involves
microtubule-associated proteins such as LC3 and actin microfilaments [79].
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Figure 2. Autophagy, a pro-survival process, is elevated in CSCs. (A) The process of autophagy from nucleation to
degradation. The process starts with the formation of an isolation membrane (regulated by the Beclin-1 complex), followed
by the formation of a double membrane named the autophagosome which encapsulates cellular constituents for degradation.
Following fusion with a lysosome, cell components in the autolysosome are degraded and recycled as nutrients and
metabolites back into the cytosol. Several autophagy-related (Atg) proteins regulate different stages of autophagy (e.g., the
Atg5-12 complex is vital for autophagosome formation). (B) Autophagy plays many roles in CSC survival. High levels of
autophagy/mitophagy in CSCs promotes resistance to chemotherapy; potential treatments include autophagy/mitophagy
inhibitors in combination with chemotherapy drugs. Induced autophagy stimulates CSC invasion and migration as well as
survival in the hypoxic microenvironment. CSCs also depend on elevated mitophagy for their metabolism and to control
ROS levels. Finally, CSCs show a mixed phenotype where both OXPHOS and glycolytic metabolism is employed in CSCs of
different cancer models.
4.2. CSCs Rely on Autophagy for Stemness, Invasion, Migration, and Chemo-Resistance
Over the past few years, autophagy has been shown to be vital for the maintenance
of stemness in both normal tissue stem cells and CSCs [80]. CSCs rely on autophagy for
various roles; they use it as a means to survive, adapt to the tumour microenvironment, for
migration and invasion as well as a route to escape radiation treatment and chemotherapy
(Figure 2B). For many cancer types, including those of the pancreas, breast, bladder,
colorectum, and brain (glioblastoma), CSCs are dependent on autophagy for maintaining
their stemness. The basal level of autophagy/mitophagy is frequently higher in CSCs
compared to that of normal tissue-specific stem cells [81]. Why stem cells are more reliant
on autophagy is a current area of interest for many scientific groups. For instance, the
interaction between transcription factor (TF) families in regulating CSC properties and
autophagic processes has been reported. Forkhead box O (FOXO) TFs regulate autophagic
proteins such as Beclin-1, LC3, ULK1, Atg5, Atg8, GABARAPL1, Atg12, Atg14, and BNIP3,
while also regulating CSC properties [82]. FOXO3 is required by leukaemia-initiating
cells for maintaining stemness, while in ovarian cancer stem cells (OCSCs), FOXO TFs are
regulated by autophagic processes. Further, the lentiviral knockdown of ATG5 led to a
decrease in OCSC chemoresistance and the ability to self-renew [83,84].
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Further, autophagy stimulates the expression of both stem cell markers such as CD44
and mesenchymal markers such as vimentin [85]. Cufi and colleagues were the first to
demonstrate a link between autophagy and the maintenance of tumours, whereby au-
tophagy promoted higher expression levels of CD44 and vimentin in BCSCs (CD44+CD24-
/low cells) isolated from the JIMT-1 epithelial breast cancer cell line. Furthermore, inhi-
bition of autophagy preferentially potentiated epithelial-like characteristics, marked by
CD44+CD24+ surface marker expression, over the mesenchymal phenotype marked by
low expression of CD24. By inhibiting autophagy using Chloroquine or by downregulating
ATG12, the migration and invasiveness of these CSCs was impaired, as was vimentin
expression [85].
Additionally, the autophagy regulators SQSTM1 and DRAM1 are highly expressed
in GBM CSCs, and their expression correlates with that of mesenchymal factors such as
c-MET [86].
There is increasing evidence to suggest that signalling pathways leading to autophagy
and epithelial-to-mesenchymal transition (EMT) are linked. EMT is a vital event during
embryonic development and is a critical feature linked to the ability of CSCs to migrate [13,
87,88]. Indeed, inhibiting autophagy in some solid tumours such as GBM and breast cancer
led to impairment of CSC migration. In addition, Helicobacter pylori-induced autophagy is
implicated in the emergence of gastric CSCs. For instance, treatment of CSCs, characterised
by CD44+ expression and tumoursphere formation capacity with autophagy inhibitors,
reduced the appearance of a mesenchymal phenotype and tumoursphere formation [89].
Recently, studies of BCSCs showed that autophagy plays a role in mediating tumour
dormancy. BCSCs can lie dormant for many years before recurring in metastatic lesions
and resort to an increased autophagic flux to survive harsh tumour environments and to
maintain their phenotype, in particular by resisting chemotherapeutics and hypoxia [90].
Furthermore, the autophagy-associated proteins Atg5, Atg12, and LC3-B are overexpressed
in dormant stem cell-like breast cancer cells, a phenotype that can be reversed by 3-
methyladenine (3-MA), an inhibitor of autophagy. Moreover, the JNK/SAPK signalling
pathway is upregulated in these dormant stem cell-like breast cancer cells and is responsible
for increasing autophagy amongst the population [91]. Similarly, the autophagy protein
Beclin-1 is expressed at higher levels in ALDH1+ BCSCs derived from mammospheres,
compared to tumour cells in the bulk population [92]. It therefore follows that inhibition of
autophagy by knockdown of ATG7 or Beclin-1 reduces the secretion of IL-6, which has a
crucial role in the maintenance of BCSCs [93].
A link between CSCs, autophagy, and drug resistance has been observed in numerous
human cancers, including leukaemia, breast, pancreatic, urinary bladder, colon, and brain
cancers [94], in which the preclinical and clinical use of autophagy inhibitors in combina-
tion with targeted therapies has been the main focus [95]. Indeed, combinations of cytotoxic
drugs and autophagy inhibitors enhanced CSC sensitivity. For instance, in GBM CSCs, the
EGFR inhibitor, TMZ, combined with Chloroquine inhibited proliferation [96]. In gastric
CSCs, Chloroquine and 5-fluorouracil (5-FU) inhibited Notch signalling and reduced cell
viability [97]. In bladder CSCs, siRNA-mediated and pharmacological inhibition of au-
tophagy restored the anti-proliferative effects of the chemotherapeutic agents gemcitabine,
mitomycin, and cisplatin [94].
Interestingly, studies have indicated that autophagy induction is involved in drug-
induced cytotoxicity. For instance, Resveratrol, a natural polyphenolic compound, which
triggers autophagy by blocking Wnt signalling inhibits breast CSC growth and survival [98,99].
In comparison with Chloroquine, newer lysosomal inhibitors such as Lys05, an analogue of
Chloroquine, are more selective and potent. Indeed, in leukaemia, Lys05-mediated autophagy
inhibition decreased the numbers of LSCs in vitro and in vivo [100,101]
4.3. Autophagy and the Hypoxic Microenvironment
In the tumour microenvironment, hypoxia is a known inducer of autophagy, mediated
by HIF-1α. HIF-1α controls the expression of genes involved in initiating and maintaining
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CSCs such as OCT4, SOX2, KLF4, MYC, NANOG, ALDH1A1, and NOTCH [102–104]. In
addition, hypoxic stress induces EMT TFs such as SNAIL, TWIST, and ZEB2 which are
direct targets of HIF-1α [105–107]. Other HIF-1α target genes including BNIP3/BNIP3L
mediate autophagy induction under hypoxic conditions, leading to cell survival [108],
while hypoxia-induced NANOG can bind the promoter of BNIP3L, revealing a regulatory
loop [109].
CSCs are particularly reliant on autophagy for survival in hypoxic states. Of note,
liver CD133+ CSCs, as well as pancreatic CSCs, critically rely on hypoxia-induced au-
tophagy for their survival [110]. Interestingly, Zhu and colleagues showed that intermittent
hypoxia reprogrammes non-stem pancreatic cancer cells into pancreatic CSCs, with in-
creased autophagic flux and HIF-1α levels [110]. Additionally, gene expression analysis
showed autophagy to be one of the major pathways induced by hypoxia in colon CSCs;
PRKCA/PKCα was shown to be involved in hypoxia-induced autophagy-mediated CSC
self-renewal whereby knockdown of ATG5 significantly reduced in vivo tumour forma-
tion [111]. Autophagy was also found to be upregulated in multiple human AML cell
lines following exposure to hypoxia. Inhibition of the late stage of autophagy with either
Chloroquine or Bafilomycin A1 treatment in leukaemia stem cells (LSCs) allowed for these
cells to overcome hypoxia-induced resistance to cytarabine (AraC) [112].
With respect to the signalling pathways involved in these processes, the PI3K/Akt/mTOR
was shown to be inhibited by hypoxia [113], while mTOR was found to interact with and
regulate HIF-1α [114,115]. In lung cancer cells, the drug Gigantol targets CSCs by inhibiting
PI3K/AKT/mTOR and JAK/STAT pathways [116]. Other targets of HIF-1α, KLF5, were
shown to be upregulated in response to hypoxic stress [117], while siRNA-mediated KLF5
knockdown, inhibited hypoxia-induced cell survival and promoted apoptosis through the
inactivation of the PI3K/Akt/mTOR pathway [118].
4.4. CSCs Are Dependent on Mitophagy for Their Metabolic Reprogramming
To maintain their proliferative needs, cancer cells rely on a constant nutritional supply
by using various strategies such as redox signalling, a high glycolytic flux, and autophagy.
Unlike most cancer cells, which mostly depend on aerobic glycolysis, CSCs show a mixed
phenotype where both CSCs undergoing OXPHOS metabolism (e.g., breast, pancreatic, and
lung CSCs) or glycolytic metabolism (e.g., glioma stem cells (GSC)) have been demonstrated
in different cancer models [81].
In addition to autophagy, mitophagy has been shown to be a key mechanism in the
homeostasis and invasion of CSCs [119]. Since mitochondria are essential for regulating
cellular energy homeostasis, mitophagy has been the subject of extensive research and
has recently been proposed to play critical roles in many diseases [120]. As the name
suggests, mitophagy is the selective degradation of mitochondria by autophagic processes.
In addition to maintaining the stability and integrity of mitochondrial function and struc-
ture, mitophagy is important for the maintenance of mitochondrial number [121] and the
elimination of mitochondria during the development of specialised cells such as reticu-
locytes [122]. Mounting evidence shows that CSCs critically depend on mitochondrial
function for their survival, migration, as well as resistance to toxic agents [123–125]. More-
over, CSCs rely on mitophagy in order to keep ROS levels under control and consequently
in the prevention of DNA damage and the induction of apoptosis [126].
Mitochondrial fission, mediated by dynamin-related protein 1 (DRP1) has been shown
to facilitate mitophagy by dividing mitochondria into fragments ready for autophagosomal
engulfment [127,128]. Glioblastoma CSCs, show activation of DRP1 which correlates
with poor survival in GBM [129]. In addition, mitophagy has been shown to regulate
hepatic CSCs by inhibiting the tumour suppressor p53 and promoting the expression of
NANOG [130]. Apart from playing a role in the survival of CSCs, mitophagy has also been
implicated in chemoresistance mediated by metabolic reprogramming, whereby mitophagy
contributes to doxorubicin resistance of colorectal CSCs [131]. Indeed, a combination of
mitophagy inhibitors with anti-tumour drugs increases CSC death [132]. For instance,
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the use of the classic chemotherapeutic drugs cisplatin, doxorubicin, and vincristine, in
combination with the mitophagy inhibitor liensinine increased the sensitivity of breast
cancer stem cells to treatment [133].
5. Long Noncoding RNAs and Cancer Stem Cells
5.1. Long Noncoding RNAs in Health and Disease: A Central Role in Cancer
Long noncoding RNAs (lncRNAs) are transcripts longer than 200 nucleotides that lack
protein-coding potential. Following their discovery, their functional role has been ques-
tioned [134,135]. LncRNAs are nowadays some of the most investigated molecules in health
and disease and have shown key potential as cancer biomarkers and therapeutic targets. In
fact, lncRNAs can be expressed in a tissue- and disease-specific manner showing aberrant
up- or down-regulation in specific cell-types and different malignancies [136–138]. Despite
numerous studies having characterised lncRNAs in cancer, their expression patterns and roles
are still largely uncharacterised. For the most part, this is due to the abundance of lncRNAs
(more than 50,000 estimated encoded by the human genome) to be studied and their ability to
simultaneously act in different cellular pathways with various mechanisms of action [139].
Among the most well characterised functions, lncRNAs can act in epigenetic regulation, tran-
scriptional and post-transcriptional regulation, miRNA synthesis and function, and protein
scaffolding, thereby regulating fundamental cellular processes such as chromatin organisation,
cell proliferation and survival, cancer growth, metastasis, and drug resistance [140–143]. CSCs
play key roles in tumour-associated processes but the mechanisms regulating and maintain-
ing CSC characteristics are largely unknown [140]. Notably, numerous lncRNAs modulate
tumour initiation, progression, metastasis, and drug resistance, via altering the expression of
self-renewal factors and ultimately the functions of CSCs [144].
5.2. LncRNAs in CSC Maintenance and Migration
5.2.1. Epigenetic Regulators
LncRNAs can be involved in cancer through epigenetic regulation in CSCs since
they can promote epigenetic factor and co-factor expression, stability, and function. The
X-chromosome inactivating specific transcript (XIST) gene is localised in the X-chromosome
inactivation centre (Xic), encodes for the XIST lncRNA, and is associated with tumour
regulation in various malignancies. In ovarian cancer, XIST promotes the stability of lysine
(K)-specific methyltransferase 2C (KMT2C) mRNA, thereby indirectly promoting histone
H3 methylation at lysine 4 and hence decreasing CSC proliferation [145]. XIST can also
alter the phenotype of CSCs by increasing paclitaxel sensitivity in patients; miR-93-5p can
reverse this pathway, demonstrating multifaceted interactions between epigenetics and
lncRNAs [145].
Histone methylation is a known epigenetic mechanism that induces transcriptional
repression via chromatin modification. In human liver CSCs, transcription of the lncRNA
CUDR was stimulated by TLR4, which promoted their proliferation in vitro and growth
in vivo, via control of histone methylation and telomere elongation [146]. TLR4 action
also prompted a stable interaction between CUDR, SUV39 h2, and histone 3, which led
to epigenetic repression in liver CSCs [146]. This function, mediated by this lncRNA,
controlled downstream pathways, including telomere length, playing a fundamental role
in controlling CSC survival [146] (Figure 3).
LncHDAC2 is another lncRNA upregulated in liver CSCs where it promotes stem cell
self-renewal by activating hedgehog signalling via acting as an epigenetic co-effector [137].
LncHDAC2 recruits the Nucleosome Remodelling and Deacetylase (NuRD) complex to
the promoter of PTCH1, a component of the hedgehog signalling pathway. Since liver
CSCs harbour resistance to common therapies, inhibition of their self-renewal capability
via lncHDAC2 targeting could suppress liver tumorigenesis [137]. Other lncRNAs also
regulate epigenetic modifications in liver CSCs such as HOTAIR, which acts by similar
mechanisms in other CSCs, such as those found in prostate cancer, that may express c-KIT
surface marker [147,148]. These studies highlighted the promiscuity of lncRNAs that can
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regulate the same specific pathways in one or more cancer types, making their study of
important translational potential for different malignancies.
Figure 3. Long noncoding RNAs (LncRNAs) contribute to CSC features via the regulation of different cellular mechanisms.
The three main mechanisms of actions of lncRNAs in CSCs regulation: Top panel: the lncRNA CUDR interacts with TLR4,
thereby enhancing its function and promoting the activity of SUV39H2. SUV39H2 is involved in epigenetic regulation that
stimulates liver cancer CSC proliferation. Centre panel: the lncRNA SOX2OT sequesters miR-200c, thereby inhibiting its
function of targeting SOX2 mRNA. Therefore, SOX2OT indirectly promotes translation of the stemness factor SOX2 in
bladder cancer. Lower panel: the genetic locus of PSORC1C3 contains an HRE responding to hypoxia-inducible factor (HIF)
transcription factors. HIF triggers a CSC phenotype via PSOR1C3 which interacts with OCT4 mRNA, thereby stabilising
it and promoting protein production and function in renal cell carcinoma cells. CSCs: cancer stem cells; HRE: hypoxia
response element.
5.2.2. miRNA Synthesis and Function
Most lncRNAs have been characterised as competing endogenous RNAs (ceRNAs)
since they can compete for miRNA binding, thereby sequestering these small ncRNAs
from binding the 3′UTR of target mRNAs. In this way, lncRNAs can indirectly promote
mRNA stability and protein translation. H19 was characterised in several cancers as being
oncogenic and a promoter of metastasis but its mechanisms of action were only partially
elucidated. In pancreatic ductal adenocarcinoma, H19 regulates metastasis in vitro and
in vivo by increasing the self-renewal potential of CSCs, sphere-formation, and the ability to
invade into surrounding tissues [149]. H19 also promotes sphere formation by pluripotent
CSCs produced from human mammary epithelial MCF-10A cells and its expression is
associated with reduced disease-free and overall survival in breast cancer patients [150].
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H19 is a precursor of miR-675 and both of these ncRNAs promote breast cancer metastasis
via induction of EMT and features of breast CSCs, both in vitro and in vivo [141].
Another lncRNA, SOX2OT promotes bladder cancer cell stemness, thereby inducing
tumour growth and metastases in vivo with its expression linked to unfavourable clinical
attributes, such as high histological grade, advanced TNM stage, and a poor progno-
sis [151]. SOX2OT is a ceRNA that sequesters miR-200c and upregulates SOX2 expression, a
fundamental transcription factor for stem cell self-renewal. SOX2 overexpression in turn re-
verses SOX2OT silencing-induced inhibition of the bladder CSC stemness phenotype [151]
(Figure 3).
Crosstalk between ncRNAs can also occur following upstream targeting by miRNAs
of lncRNAs, such as CCAT2 and LUCAT1. CCAT2 is an lncRNA aberrantly expressed in
triple-negative breast cancer (TNBC), which is known to be highly aggressive [136]. CCAT2
levels are higher in breast CSCs while promoting the expression of CSC-associated proteins
such as OCT4, NANOG, and KLF4, and inducing mammosphere formation [136]. CCAT2
upregulates the expression of the OCT4 pseudogene, OCT4-PG1, which in turn is targeted
by miR-205. miR-205 is also known to target NOTCH2, another gene upregulated by CCAT2
in TNBC [136]. Likewise, LUCAT1 is an lncRNA associated with clinical features of breast
cancer patients, such as tumour size, lymph node metastasis and TNM staging, and a
poor prognosis [152]. In vitro, LUCAT1 promotes breast cancer cell proliferation and is
aberrantly upregulated in breast CSCs where it promotes self-renewal by regulating the
Wnt/β-catenin pathway [152]. LUCAT1 can be targeted by miR-5582 which inhibits its
expression. Hence, LUCAT1 represents a putative prognostic biomarker and a novel target
for treatment strategies in clinical practice [152].
5.2.3. Transcriptional Regulators
LncRNAs play multifaceted roles in transcriptional regulation, from the stabilisation
of transcription factors to modulation of gene expression and splicing. HIF transcription
factors play a central role in promoting hypoxia and participating in other oncogenic
pathways [143,153]. In renal cell carcinoma, HIF transcription factors affect the expression
of the stem cell transcription factor OCT4, which correlated with advanced tumour stage
and poor overall survival of renal cell carcinoma patients [143]. PSOR1C3 is an lncRNA
upstream of OCT4, containing an HIF-responsive long terminal repeat (LTR) element in its
promoter. Therefore, PSOR1C3 expression is regulated by HIF transcription factors and
can in turn affect transcription of OCT4 variants, due to a transcription factor-lncRNA-
transcription factor-mediated positive regulation mechanism [143] (Figure 3).
Although most lncRNAs have been shown to promote oncogenic factors and processes,
some lncRNAs can also hinder cancer and CSC features. An example is the lncRNA lnc-
DILC [154]. Microarray and RT-qPCR validation, conducted on liver CSCs, revealed
downregulation of lnc-DILC; Lnc-DILC inhibited the expansion of liver CSCs via inhibition
of IL-6/STAT3 signalling, by directly binding the IL-6 promoter [154]. Lnc-DILC was also
downregulated in hepatocellular carcinoma patient tumours and correlated with patient
prognosis [154].
5.2.4. LncRNA-Mediated Regulation of CSCs Modulates Drug Resistance
Several studies have implicated lncRNAs in cancer drug resistance and recent findings
showed that lncRNAs can modulate treatment-resistant phenotypes via regulation of CSC
biology and function [145,155,156].
In evidence, for pancreatic cancer, the lncRNA RP11-567G11.1 is upregulated in
poorly differentiated tissues and promotes proliferation and cell cycle progression, induces
apoptosis and a stem cell-like phenotype by triggering factors downstream of the Notch
signalling pathway [155]. Depletion of RP11-567G11.1 increased gemcitabine response
suggesting its potential value as a therapeutic target in drug-resistant tumours [155].
Furthermore, microarray analysis of cholangiocarcinoma and adjacent healthy tissues
revealed differential expression of the lncRNA lnc-PKD2-2-3, which was confirmed in
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60 paired samples by reverse transcription-quantitative polymerase chain reaction (RT-
qPCR) [157]. Modulation of lnc-PKD2-2-3 expression via lentiviral overexpression or
hairpin RNA silencing revealed that this lncRNA induced the expression of CSC identifying
proteins such as CD44, CD133, and OCT4, thereby inducing sphere formation and drug
resistance to 5-fluorouracil (5-FU) [157]. In this study, lnc-PKD2-2-3 was confirmed to
promote oncogenic and stem-like characteristics such as poor tumour differentiation,
advanced TNM stage, increased carcinoembryonic antigen expression, and was associated
with poor overall survival for cholangiocarcinoma patients. Indeed, lnc-PKD2-2-3 was
upregulated in cholangiocarcinoma stem-like cells [157]. This lncRNA could be a future
therapeutic target and biomarker of CSC prevalence in cholangiocarcinoma and in other
tumours where it promotes stemness [157].
In pancreatic cancer, the lncRNA MALAT-1 exerts oncogenic functions via promotion
of EMT and stimulation of CSC-associated protein expression suggesting a role for this
lncRNA in stimulating stem-like phenotypes [140]. MALAT-1 promoted spheroid formation
and resistance to gemcitabine in pancreatic cancer cells as well as tumorigenicity in vivo
by stimulating the expression of self-renewal-associated stem cell transcription factors
and other proteins, including OCT4, NANOG, SOX2, BMI1, β-catenin, and c-Myc [140].
The roles of lncRNA in cancer aggressiveness such as drug resistance is of fundamental
importance to finding novel therapeutic approaches to overcome resistance and increase
patient survival.
5.3. LncRNAs as Cancer and CSC-Specific Therapeutic Targets and Biomarkers
Since lncRNAs do not encode for proteins, classical pharmacological treatments target-
ing protein structure or activity are not effective. Nevertheless, this paves the way for the
use of novel approaches that could be tested in clinical trials to modulate lncRNA expres-
sion, with promising advantages for precision medicine. Many lncRNAs are upregulated
as components of specific oncogenic pathways in CSCs. Therefore, their inhibition could
be exploited for therapy either as a single target or in combination with other treatments to
improve patient response to therapy and survival, potentially with reduced side-effects. At
present, therapeutic targeting of lncRNAs is largely being explored at a preclinical stage,
although some successful methods of lncRNA inhibition are currently undergoing studies
in clinical trials, such as the use of antisense oligonucleotides (ASOs) [158,159]. ASOs
are single-stranded DNA polymers (13-200nt), which are readily internalised by cells in
which they bind to their target RNA, thereby inducing DNA/RNA complex degradation,
mediated by RNase-H [160]. RNase-H is an enzyme expressed both in the nucleus and
cytoplasm [161], thereby leading ASOs to target both nuclear and cytoplasmic lncRNAs.
Features of ASOs have been improved in recent studies via chemical modification. In
this way, a new generation of antisense molecules has been created, such as locked nu-
cleic acids (LNAs), Phosphorothioate (PS) ASOs, and morpholino oligomers. LNAs are
single-stranded oligonucleotides with increased stability and strength of hybridisation
due to a stretch of DNA flanked by LNA nucleotides which confer specific complemen-
tarity and RNase H-mediated degradation of the target sequence [162]. PS ASOs have
increased molecular stability, due to the substitution of one oxygen of the phosphodiester
bond between two ribose molecules with a sulphur group that creates a phosphorothioate
bond [163], thereby increasing molecular resistance to nuclease digestion and stronger
serum protein binding. This provides PS ASOs with increased stability in the circulation
promoting tissue and cellular uptake [163]. Similar characteristics can be obtained by other
chemical changes to obtain morpholinos, characterised by the replacement of deoxyribose
with a six-membered morpholine ring, and of the charged phosphodiester inter-nucleoside
linkage with phosphorodiamidate linkages. Therefore, a non-ionic structure is created of
25bp length, able to sterically block ribosomal assembly, affect RNA splicing and bind
to complementary RNAs with increased affinity and stability, upon serum and plasma
nuclease and protease activity [164,165]. Morpholinos have been successfully used for tar-
geting c-Myc in lung and prostate cancer preclinical models with a phase I trial underway
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for prostate cancer [164,165]. The effect of antisense molecules has also been tested for
lncRNAs in cancer and specifically CSCs. NRAD1 is an lncRNA upregulated in TNBC
CSCs and is associated with a poor patient prognosis [166]. Antisense oligonucleotides
targeting NRAD1 reduced survival and TNBC tumour growth as well as affecting CSC char-
acteristics by regulating nuclear functions such as enriching chromatin interactions [166].
Other methods have been considered for targeting lncRNAs with a therapeutic aim, such as
the transient use of siRNAs or stable transduction with lentiviral vectors or CRISPR-Cas9
genome editing, but their use in the clinic is still a way off [167–169].
Closer to clinical investigation and approval is the use of lncRNAs as cancer and CSC
biomarkers in patients. As mentioned previously, lncRNAs can be aberrantly upregulated
in specific cancer cells, including CSCs [136–138]. Due to their specific expression, they
are optimal candidates for prognostic and diagnostic biomarkers. Clinical trials are cur-
rently recruiting patients for lncRNA-based cancer diagnosis (https://clinicaltrials.gov/ct2
/show/NCT03830619 accessed on 5 February 2019 https://clinicaltrials.gov/ct2/show/
NCT04269746 accessed on 8 July 2020) and the lncRNA PCA3 was also clinically approved
for cancer diagnosis [170]. Notably, lncRNAs were detected in biological fluids, suggesting
that they could be used as non-invasive biomarkers for different malignancies [171,172].
H19 stimulates the expression of stemness markers such as CD133, NANOG, OCT4, and
SOX2 inducing the clone-forming ability of glioma and breast CSCs [144].
HOTTIP is highly upregulated in pancreatic CSCs and promotes stemness features,
such as the ability to form spheroids, tumours, and expression of stemness-related tran-
scription factors (LIN28, NANOG, OCT4, and SOX2) and other proteins (ALDH1, CD44,
and CD133) via binding WDR5 and so stimulating HOXA9, activating the Wnt/β-catenin
pathway. The role of HOTTIP was confirmed in vitro using human pancreatic cancer cell
lines (i.e., PANC-1 and SW1990) in promoting sphere formation, and in vivo by growth of
engrafted sphere cells [173].
Since lncRNAs can promote the expression of proteins associated with the CSC pheno-
type, their detection could aid in the identification of CSCs in patient-derived tumours by
simple non-invasive diagnostic tests. In evidence, several studies have found lncRNAs se-
creted in tumour-associated exosomes secreted into the peripheral circulation [171,174,175].
In this regard, a recent study showed that in hepatocellular carcinoma, H19 was upregu-
lated in CD90+ CSC-like cells and was released in exosomes [172]. These cells were able
to modulate the surrounding microenvironment thereby promoting angiogenesis and cell
adhesion. Moreover, modulation of H19 expression showed that this lncRNA affected the
exosome-mediated mechanism of angiogenesis [172]. Exosomes can facilitate the transport
of lncRNAs away from the tumour microenvironment, making their non-invasive detection
a real opportunity for the clinical diagnosis of cancer and the identification of CSCs.
6. The Interrogation of Gene–Disease Networks for CSC-Associated Genes
In this section, we have endeavoured to draw links between the CSC factors and
markers of stemness with prominent genes involved in CSC-related autophagy processes,
interaction with the microenvironment, and CSC-associated lncRNAs. To that end, we
conducted network analyses using multiple platforms on genes discussed in this review,
inclusive of CD34, CD38, B7H4, LETM1, CD90, ST6GALNAC1, CD44, SOX2, KLF4, OCT4,
CD133, CD24, ESA, CD13, EpCAM, NANOG, ITGA6, SNAI1, NOTCH3, CDKN1A, c-KIT,
STAT3, SALL4, ALDH1, vimentin, ATG5, ATG12, LC3-B, Beclin-1, ATG7, SQSTM1, DRAM1,
c-MET, HIF-1α, PRKCA, DRP1, XIST, CUDR, LncHDAC2, HOTAIR, H19, miR-675, SOX2OT,
CCAT2, PSOR1C3, miR-205, NOTCH2, miR-5582, lnc-DILC, RP11-567G11.1, lnc-PKD2-2-3,
MALAT-1, BMI1, c-Myc, HOTTIP, KMT2C, miR-93-5p, TLR4, SUV39 h2, PTCH1, mir-200c,
LUCAT1, OCT4-PG1, β-catenin, NRAD1, LIN28, WDR5, HOXA9, and Wnt.
We used the Reactome database in Cytoscape to interrogate the functional interactions
between these genes, under two assumptions; A) genes that were not included in this
study could be added to the network, or B) only genes included in this study could be
included in the network (Figure 4) [176–178]. These gene products may be involved in
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several interconnected biochemical pathways that may be activated in different contexts.
For instance, there is evidence that SOX2 may activate NANOG, or that PRKCA may
activate ITGA6. Collectively, these data demonstrate the functional association between
these genes.
Figure 4. Reactome analysis of stemness proteins, CSC markers, autophagy genes, and lncRNAs discussed in this review
(A) Reactome analyses of genes reviewed in this study and other genes that may provide a link between the genes discussed.
(B) Reactome analyses performed using only genes reviewed in this study. Both analyses indicate functional interactions
drawn from the Reactome database in Cytoscape. In this figure, edges indicate an interaction between two genes or their
transcribed products. Dashed edges depict computationally predicted interactions with a probability of 0.95; solid edges
indicate a shared protein complex or binding event. Arrowed edges indicate activation or catalytic activity, while blunted
arrows indicate inhibition. Gene names in black are genes that were discussed in this review, while genes in red were
not discussed in this review but were included because they provide a link between the genes discussed. Genes with no
functional interactions are not shown.
We extended our network analysis to understanding the functional and physical
protein–protein interactions using STRING v11.04 (Figure 5A) [179]. For the submitted list,
the results indicate a greater than expected interaction for a network of this magnitude,
suggesting a highly interactive group of proteins (51 nodes, 70 interactions, 15 expected
interactions, p-Value < 10−16). For instance, SNAI1 strongly interacts with SALL4, while
the interaction between STAT3 and Beclin-1 is weaker.
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Figure 5. Functional and physical protein–protein interactions and DisGeNat analysis. (A) Physical and functional protein–
protein interactions in the subset of genes that were reviewed in this work obtained using the STRING database v11.04.
Nodes represent proteins, while the thickness of edges indicates the strength of the data obtained from a modified naïve
Bayes algorithm. The evidence underlying the network was restricted to interactions in humans that were derived from
curated databases (Biogrid), in addition to physical experiments, and co-expression (excluding text-mining, predicted, and
orthologous evidence); 51 nodes, 70 interactions, 15 expected interactions, p-Value < 10−16. (B) A network generated by
DisGeNet, depicting common diseases for which the network of genes was enriched. This information was obtained from
the DisGeNet databases, using the ClusterProfiler package in R. The comparison includes a subset of 47 protein-coding
genes discussed in this review that were curated in the DisGeNet database. The top 20 most enriched diseases were labelled,
with the size of their corresponding gold node representing the adjusted −log10 p-Value of enrichment, while unlabelled
grey nodes represent genes implicated in these cancer states. In total, 191 disease states were enriched (Bonferroni corrected
p-Value < 0.005).
In addition, we sought to interrogate disease–gene interactions of the genes mentioned
above, utilising DisGeNet database using clusterProfiler package [180,181]. This analysis
revealed the most highly enriched diseases, represented by gold nodes, that were associated
with these genes. These include gastric adenocarcinoma and urothelial carcinoma (Figure 5B)
(Bonferroni correction p-Value < 0.0005). Finally, we found transcription factor targets and
putative miRNA target predictions by Genemenia using MSigDB8 databases, with targets
displayed in red [182,183]. For instance, mir449 is a target of KLF4 and MET (Figure 6).
Using these tools, we have sought to drive the message that the stemness genes,
genes involved in the maintenance of stemness, genes associated with autophagy-related
processes and lncRNAs, are strongly interlinked and also show a strong association with
cancers. This interlinkage is multifaceted, ranging from co-expression to physical binding
events to interactions along biochemical pathways mediated by additional proteins. Ul-
timately, these data show that a complex interplay between signalling pathways drives
tumour growth in heterogeneous cell populations and therefore that any therapeutic
approach must take into account all of these factors to be successful.
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Figure 6. Genemania interrogation of transcription factor and miRNA targets. Transcription factor and miRNA target
prediction from MSigDB using GeneMania. Targets are displayed in red, while genes are displayed in blue.
7. The Triangle of CSCs, Autophagy, and lncRNA
In light of the evidence presented in Sections 2–6, we aim to further substantiate
the links between the triangle of CSC phenotype/potential, autophagy, and lncRNA and
their networks. We learned that autophagy, chiefly triggered by hypoxia, is employed
by CSCs as a means to adapt to harsh TME conditions and can (through HIFs) maintain
stemness factors. Hypoxia-triggered HIFs, then directly or through their extensive tar-
gets, stimulate the maintenance of stemness markers such as OCT4, SOX2, KLF, NOTCH,
and NANOG [27,184]. HIF target genes in turn could induce autophagy under hypoxic
conditions, demarcating a feedback loop. On the other hand, the role of lncRNAs in
CSC phenotype establishment such as their contribution to CSC self-renewal has been
reported. Here we reviewed the regulation of stemness markers such as NANOG and
OCT4 by H19, HOTTIP, and CCAT2 [136,144,173]. In addition, MALAT-1, H19, and CUDR
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can maintain the length of telomeres, therefore contribute to CSC subpopulation mainte-
nance [25]. These observations highlight the contribution of two key mechanisms to the
maintenance of stemness markers such as OCT4 and NANOG, by hypoxia-driven HIF TFs
(and through that autophagy), or by H19, HOTTIP, and CCAT2 lncRNAs. Indeed, coopera-
tion between lncRNAs and HIFs have been documented. For instance, P53-HIF-H19/IGF2
signalling pathway has been described in glioma [185], while it has been reported that
HIFs can directly bind to the promoter of PSOR1C3 to promote stemness factors [143].
Collectively these observations form a triangle inclusive of hypoxia-driven HIFs, lncRNA,
and autophagy, that through interlinked mechanisms, can maintain CSC stemness factors.
In Figure 7, we have sought to summarise the triangle of the interactions between CSC
phenotype/potential, autophagy, and lncRNA with respect to stemness markers.
Figure 7. The contribution of autophagy and lncRNA to stemness factors in the tumour microenvironment (TME). In
response to hypoxia, HIFs and their targets are triggered that can contribute to stemness factors. In turn, hypoxia-driven
HIFs can trigger autophagy, as a means to survive the harsh conditions that and contribute to stemness factors. LncRNAs
such as H19, HOTTIP, and CCAT2, could directly contribute to stemness factors.
Another interesting aspect may be the convergence of the members of this triangle,
on the EMT axis. EMT is triggered by hypoxia and it can trigger TFs such as SNAI1 and
TWIST1. Further, key mediators of signalling pathways or stemness factors inclusive of
TGF-B, STAT3, Notch, and NANOG, are triggered by EMT that can in turn contribute to
the maintenance of the CSCs [27,184,186]. Activated STAT3 can contribute to EMT and
can bind to the promoter of TWIST1. Further, STAT3 in cooperation with HIF-1α can
increase the expression of CD133, a marker of CSCs [187]. Moreover, Atg4, Beclin-1, and,
P62 can influence EMT and contribute to CSC maintenance in breast cancer [188], while in
pancreatic cancer, lncRNA MALAT-1, can promote EMT and CSC-associated proteins [140].
Collectively, we can conclude that lncRNA and autophagy, and hypoxia-induced HIF-1α
can influence EMT through interconnected mechanisms and signalling pathways, leading
to the maintenance of CSC properties (Figure 8).
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Figure 8. The interlinkage between the triangle of CSCs, lncRNAs, and autophagy with respect to epithelial-to-mesenchymal
transition (EMT). Hypoxia in the TME can trigger SNAI1 and TWIST1 and relevant signalling pathways. STAT3 activation
can contribute to EMT, while it can activate TWIST1. Further, STAT3 and HIFs directly or in combination can contribute to
CSC factors. LncRNA MALAT-1 can promote EMT and CSC factors. Autophagy mediators such as Beclin-1, P62, and Atg4
can contribute to both EMT and CSC factors.
Finally, we hypothesise that CSCs, autophagy, and lncRNA may collaborate on the
axis of inflammation. In a study utilising the co-culture of MCF-7 breast cancer cell line
and immortalised foreskin fibroblasts, inflammatory mediators such as IL-6 and IL-8 were
upregulated in the extracellular matrix, while autophagy was induced due to oxidative
stress [189]. We also learned that in BCSCs derived from mammospheres, the inhibition
of autophagy led to the reduction in IL-6 secretion affecting the maintenance of these
CSC [92,93]. Hence, we can hypothesise that through crosstalk between CSCs and cancer-
associated fibroblasts, or perhaps other mechanisms, cytokines such as IL-6 can support
CSC maintenance. In addition, an lncRNA, lnc-DILC, that through binding to the promoter
of IL-6 reduced the expansion of liver CSCs [154], suggesting potential negative feedback
loops. Through these examples, we have endeavoured to further substantiate the notion
of functional links between lncRNA, autophagy, and CSCs through interaction with the
microenvironment.
8. Discussion and Conclusions
If we accept that a sub-population of cancer-initiating cells or CSCs are endowed
with capacities to initiate or propagate tumours, respectively, and to self-renew, while
persister cells resist treatment, then directing our collective efforts towards developing
and fine-tuning treatment strategies that specifically target and eradicate these cells is
paramount [33]. Irrespective of theoretical and practical definitions of these cells with
stem-like characteristics and related disputes, treatment response, metastasis, evasion of
immunosurveillance, and the resulting impact on patient prognosis and well-being are
important topics that the cancer community faces. Failed cancer therapies, in many cases,
are due to the inability of the treatment to eliminate the CSCs, leading to inevitable relapse.
For instance, many cancer therapies are aimed at targeting highly proliferative cells of
the cancer population and thereby may not effectively target quiescent CSCs [190]. One
good example of this is the treatment of pancreatic cancer cells in vitro and in vivo with
gemcitabine. This effort led to apoptosis only in the non-CSC population of the tumour
in vitro and led to the enrichment of a CD133+ CSC fraction in vivo in the mouse xenograft
model [37]. This and numerous other studies indicate large gaps in our understanding
of CSCs, their associated cellular processes, interaction with the microenvironment, and
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regulatory mechanisms that govern their maintenance. CSCs in their TME are affected
by a myriad of intrinsic and extrinsic cues. Examples of extrinsic factors include hypoxia,
stress stimuli, nutrient supply, or variable levels of growth factors. Concomitantly, these
environmental factors can influence the CSCs to activate stress response pathways to
circumvent cell cycle arrest or death. For instance, CSCs in response to hypoxia can
instigate an HIF-1α -mediated angiogenesis processes to promote survival [27]. Moreover,
dormancy, maintenance, and survival in the harsh tumour microenvironment for CSCs
is dependent on autophagic processes [90,92,93]. CSCs in the liver and pancreas rely on
hypoxia-induced autophagy for survival and reprogramming [110], hence, as discussed,
inhibiting autophagy as a pro-survival mechanism of CSCs, in the form of combination
therapy may increase therapy success. For instance, in a study conducted by Jang and
colleagues, the apoptotic rate and autophagy induced by a bromodomain and extraterminal
domain (BET) inhibitor, JQ1, in CD34+ CD38- leukaemic blasts (LSCs) in AML were
investigated, although as mentioned in Section 3, the universal markers of CSCs in this
cancer remain inconclusive [30,191]. The authors reported that JQ1 increased cell death in
JQ1-sensitive LSC blasts [192]. However, in JQ1-resistant AML LSCs, autophagy mediators
such as Beclin-1 were upregulated, while lipidation of LC3 was increased, whereas only
minor levels of apoptosis were detected. Interestingly, the inhibition of autophagy led
to increased apoptosis in the JQ1-resistant LSCs, revealing the potential for utilising JQ1
and an autophagy inhibitor combination to effectively target CSCs in AML [192]. Despite
this success, it remains challenging to specifically target only the pro-survival aspects
of autophagy with respect to CSCs. For instance, autophagy induction can lead to the
elimination of cancer cells or lead to cancer cell survival, in the early or late stages of cancer,
respectively [27].
The regulatory network between miRNAs, lncRNAs, and the TME is also another
angle that may be leveraged for therapeutic gain. For example, in chronic myelogenous
leukaemia (CML), leukaemic stem cells (LSCs), may remain quiescent in the bone marrow,
despite efforts to target BCR-ABL kinase activity by tyrosine kinase inhibitors (TKI). Resis-
tance to TKI therapy in CML can occur due to LSCs quiescence induced by increased levels
of mir-126 [193]. It follows that the source of miR-126 was Sca-1-negative endothelial cells
of the bone marrow, which promoted quiescence and leukaemic growth. The knockdown
or silencing of miR-126 reduced leukaemia tumour-initiating capacity through engraftment
of CML LSCs in the mouse host [193]. The mechanism underlying this regulation was
shown to be the phosphorylation of SPRED1 by BCR-ABL that inhibited a modulator of
mir-126, RAN/EXP-5/RCC1. Specifically, SPRED1 is a negative regulator of RAS proteins,
while BCR-ABL phosphorylates SPRED1, allowing for the binding of this protein to RAN,
which in turn interferes with mir-126 shuttling and maturation mediated by RAN/EXP-
5/RCC1 [193]. Hence the modulation of mir-126 in combination with TKI therapy may
allow for the effective targeting of quiescent LSCs in CML.
In a second study, the role of a tumour-suppressor, MIR300, in CML LSCs (CD34+
cells) was investigated. This miRNA displayed dose-dependent antiproliferative function,
through CCND2/CDK6 inhibition and while it activated protein phosphatase 2A (PP2A),
through SET inhibition, to induce apoptosis [194]. Further, MIR300 expression led to
expanded G0-G1 stem cell fraction, while its function was limited by an lncRNA, TUG1.
MIR300 was upregulated in CML LSCs as a means to induce quiescence, whereas BCR-ABL
could downregulate MIR300 in CML stem cells to inhibit growth arrest and apoptosis [194].
Interestingly, quiescent LSCs were able to selectively suppress the proapoptotic function
of MIR300 to prevent apoptosis, while allowing these cells to exit the cell cycle. The
disruption of TUG1-MIR300 interplay, could in turn lead to PP2A-dependent eradication
of CML quiescent LSC in vitro and in mouse xenograft models. Hence, this TUG1/miR-
300/PP2A regulatory network impairs LSC quiescence, thereby making this signalling
pathway important for CML development and treatment [194].
Targeting lncRNAs may also have an unexpected advantage with respect to asymmet-
ric division of CSCs, a process that may be regulated, in part, by lncRNAs. In evidence, the
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lnc34a, upregulated in colon CSCs, directly silenced mir-34a by recruiting DNMT3A and
HDAC1 to methylate and deacetylate its promoter, independent of P53, the transcriptional
regulator of this miRNA [195]. Subsequently, this led to an imbalance in lnc34a spatial
dissemination, impacting CSC asymmetric divisions. This observation lends support to
the targeting of CSC-specific properties such as asymmetric division and self-renewal,
through the modulation of the associated lncRNAs [195]. Another example and a potential
treatment strategy could be the modulation of linc00617, an lncRNA that binds to the
promoter of SOX2, thus contributing to the self-renewal of CSCs in breast cancer [196].
An additional layer of complication occurring in parallel to these diverse events,
includes clonal evolution of CSCs, akin to the premise of tumour evolution within a
tumour, leading to heterogeneity within the CSC population [197]. CSCs gain genomic
alterations that offer growth and survival advantages, receiving input during this process
from both the TME, signalling pathways, and intrinsic regulatory networks. Heterogeneity
can be detected within the CSC population in GBM, in which SOX2, OCT4, pSTAT3, KLF4,
NANOG, and SALL4 expression defined CSC populations, while OCT4 levels varied
between CSCs [42]. In evidence, Philadelphia-positive acute lymphoblastic leukaemia
(ALL) primary patient tissue representing a single clinical entity with identifiable and
recurrent genomic alterations, was used as a model to understand clonal evolution and
in vivo growth. This study identified genetically diverse subclones within patient samples
at diagnosis that varied in cancer-initiating cell counts and self-renewal capacity through
in vivo growth in xenograft models [198], suggesting that eradicating all these subclones
could prevent further tumour evolution [198]. It is therefore plausible that heterogeneity
amongst CSCs, cancer-initiating cells, and persister cells, can impact therapy response, a
process that can be tracked using next-generation sequencing approaches.
In conclusion, we endeavoured to delve deeper into understanding the characteristics
of CSCs and methods used to identify and study these cells. We have provided specific
examples to support the properties of CSCs in multiple solid and haematological cancers.
We reviewed the implication of important cellular processes such as autophagy in the
maintenance of CSCs and the current evidence supporting the roles that lncRNAs may
play in CSC homeostasis alongside potential areas for therapeutic intervention. Using
computational analysis, we have reinforced and substantiated the inherent links between
these processes using protein–protein interactions and gene–disease association networks
in this work. Finally, we have provided a unique view on a triangle of interlinked factors
captured in this study inclusive of CSC properties, lncRNA, and autophagy.
Author Contributions: L.J., T.I., P.P., R.M.T., J.P., M.L.C., J.A.W., G.V.G., L.T., and S.D.T. wrote the
paper. All authors have read and agreed to the published version of the manuscript.
Funding: No funding was associated with this work.
Institutional Review Board Statement: Not applicable
Informed Consent Statement: Not applicable
Acknowledgments: G.V.G. acknowledges support from the NIHR Birmingham ECMC, NIHR Birm-
ingham SRMRC, Nanocommons Horizon 2020-EU (731032), the NIHR Birmingham Biomedical
Research Centre, and the MRC HDR UK (HDRUK/CFC/01), an initiative funded by UK Research
and Innovation, Department of Health and Social Care (England) and the devolved administrations,
and leading medical research charities. The views expressed in this publication are those of the
authors and not necessarily those of the NHS, the National Institute for Health Research, the Medical
Research Council, or the Department of Health.
Conflicts of Interest: The authors declare no conflict of interest.
Cancers 2021, 13, 1239 23 of 31
Abbreviations
CSCs Cancer stem cells
TICs Tumour initiating cells
LncRNA Long noncoding RNA
TME Tumour microenvironment
NOD/SCID Nonobese diabetic/severe combined immunodeficient mice model
ROS Reactive oxygen species
AML Acute myeloid leukaemia
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TFs Transcription factors
LSCs Leukaemic stem cells
TKI Tyrosine Kinase inhibitor
DNMT3A DNA methyltransferase 3A
HDAC1 Histone deacetylase 1
ALL Acute lymphoblastic leukaemia
IL-6 Interleukin 6
References
1. Yap, T.A.; Futreal, P.A.; Pusztai, L.; Swanton, C.; Gerlinger, M. Intratumor heterogeneity: Seeing the wood for the trees. Sci. Transl.
Med. 2012, 4, 127ps10. [CrossRef]
2. Greaves, M.; Maley, C.C. Clonal evolution in Cancer. Nature 2012, 481, 306–313. [CrossRef] [PubMed]
3. Gupta, P.B.; Fillmore, C.M.; Jiang, G.; Shapira, S.D.; Tao, K.; Kuperwasser, C.; Lander, E.S. Stochastic state transitions give rise to
phenotypic equilibrium in populations of cancer cells. Cell 2011, 146, 633–644. [CrossRef] [PubMed]
4. Nguyen, L.V.; Vanner, R.; Dirks, P.; Eaves, C.J. Cancer stem cells: An evolving concept. Nat. Rev. Cancer 2012, 12, 133–143.
[CrossRef] [PubMed]
5. Beck, B.; Blanpain, C. Unravelling cancer stem cell potential. Nat. Rev. Cancer 2013, 13, 727–738. [CrossRef] [PubMed]
6. Allan, A.L.; Vantyghem, S.A.; Tuck, A.B.; Chambers, A.F. Tumor dormancy and cancer stem cells: Implications for the biology
and treatment of breast cancer metastasis. Breast Dis. 2006, 26, 87–98. [CrossRef]
7. Cho, R.W.; Clarke, M.F. Recent advances in cancer stem cells. Curr. Opin. Genet. Dev. 2008, 18, 48–53. [CrossRef] [PubMed]
8. Shiozawa, Y.; Berry, J.E.; Eber, M.R.; Jung, Y.; Yumoto, K.; Cackowski, F.C.; Yoon, H.J.; Parsana, P.; Mehra, R.; Wang, J.; et al.
The marrow niche controls the cancer stem cell phenotype of disseminated prostate. Cancer Oncotarget 2016, 7, 41217–41232.
[CrossRef] [PubMed]
9. Diehn, M.; Cho, R.W.; Lobo, N.A.; Kalisky, T.; Dorie, M.J.; Kulp, A.N.; Qian, D.; Lam, J.S.; Ailles, L.E.; Wong, M.; et al. Association
of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458, 780–783. [CrossRef]
Cancers 2021, 13, 1239 24 of 31
10. Huntly, B.J.; Gilliland, D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat. Rev. Cancer 2005, 4, 311–321.
[CrossRef] [PubMed]
11. Bao, S.; Wu, Q.; McLendon, R.E.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N. Glioma stem cells
promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444, 756–760. [CrossRef] [PubMed]
12. Barker, N.; Ridgway, R.A.; van Es, J.H.; van de Wetering, M.; Begthel, H.; van den Born, M.; Danenberg, E.; Clarke, A.R.; Sansom,
O.J.; Clevers, H. Crypt stem cells as the cells-of-origin of intestinal Cancer. Nature 2009, 457, 608–611. [CrossRef] [PubMed]
13. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast
cancer cells. PNAS 2003, 100, 3983–3988. [CrossRef]
14. Clarke, M.F.; Dick, J.E.; Dirks, P.B.; Eaves, C.J.; Jamieson, C.H.; Jones, D.L.; Visvader, J.; Weissman, I.L.; Wahl, G.M. Cancer stem
cells–perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006, 66, 9339–9344.
[CrossRef] [PubMed]
15. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5, 275–284. [CrossRef]
16. Visvader, J.E.; Lindeman, G.J. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat. Rev.
Cancer 2008, 8, 755–768. [CrossRef]
17. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic
cell. Nat. Med. 1997, 3, 730–737. [CrossRef] [PubMed]
18. Bruttel, V.S.; Wischhusen, J. Cancer stem cell immunology: Key to understanding tumorigenesis and tumor immune escape?
Front. Immunol. 2014, 5, 360. [CrossRef] [PubMed]
19. Vallette, F.M.; Olivier, C.; Lézot, F.; Oliver, L.; Cochonneau, D.; Lalier, L.; Cartron, P.F.; Heymann, D. Dormant, quiescent, tolerant
and persister cells: Four synonyms for the same target in Cancer. Biochem. Pharmacol. 2019, 162, 169–176. [CrossRef]
20. Rycaj, K.; Tang, D.G. Cell-of-Origin of Cancer versus Cancer Stem Cells: Assays and Interpretations. Cancer Res. 2015, 75,
4003–4011. [CrossRef] [PubMed]
21. Quintana, E.; Shackleton, M.; Sabel, M.S.; Fullen, D.R.; Johnson, T.M.; Morrison, S.J. Efficient tumour formation by single human
melanoma cells. Nature 2008, 456, 593–598. [CrossRef] [PubMed]
22. Tang, D.G. Understanding cancer stem cell heterogeneity and plasticity. Cell 2012, 22, 457–472. [CrossRef] [PubMed]
23. Eades, G.; Zhang, Y.S.; Li, Q.L.; Xia, J.X.; Yao, Y.; Zhou, Q. Long non-coding RNAs in stem cells and Cancer. World J. Clin. Oncol.
2014, 5, 134–141. [CrossRef] [PubMed]
24. Wang, Y.; He, L.; Du, Y.; Zhu, P.; Huang, G.; Luo, J.; Yan, X.; Ye, B.; Li, C.; Xia, P.; et al. The long noncoding RNA lncTCF7 promotes
self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell. 2015, 16, 413–425. [CrossRef]
[PubMed]
25. Castro-Oropeza, R.; Melendez-Zajgla, J.; Maldonado, V.; Vazquez-Santillan, K. The emerging role of lncRNAs in the regulation of
cancer stem cells. Cell Oncol. 2018, 41, 585–603. [CrossRef]
26. Lecerf, C.; Le Bourhis, X.; Adriaenssens, E. The long non-coding RNA H19: An active player with multiple facets to sustain the
hallmarks of Cancer. Cell Mol. Life Sci. 2019, 76, 4673–4687. [CrossRef] [PubMed]
27. Zaarour, R.F.; Azakir, B.; Hajam, E.Y.; Nawafleh, H.; Zeinelabdin, N.A.; Engelsen, A.S.T.; Thiery, J.; Jamora, C.; Chouaib, S. Role of
Hypoxia-Mediated Autophagy in Tumor Cell Death and Survival. Cancers 2021, 13, 503. [CrossRef] [PubMed]
28. Hanekamp, D.; Cloos, J.; Schuurhuis, G.J. Leukemic stem cells: Identification and clinical application. Int. J. Hematol. 2017, 105,
549–557. [CrossRef] [PubMed]
29. Dick, J.E. Acute myeloid leukemia stem cells. Ann. N. Y. Acad. Sci. 2005, 1044, 1–5. [CrossRef] [PubMed]
30. Terpstra, W.; Prins, A.; Ploemacher, R.E.; Wognum, B.W.; Wagemaker, G.; Löwenberg, B.; Wielenga, J.J. Long-term leukemia-
initiating capacity of a CD34− subpopulation of acute myeloid leukemia. Blood 1996, 87, 2187–2194. [CrossRef]
31. Piao, L.; Yang, Z.; Jin, J.; Ni, W.; Qi, W.; Xuan, Y. B7H4 is associated with stemness and cancer progression in esophageal squamous
cell carcinoma. Hum. Pathol. 2018, 80, 152–162. [CrossRef]
32. Yang, Z.; Ni, W.; Cui, C.; Qi, W.; Piao, L.; Xuan, Y. Identification of LETM1 as a marker of cancer stem-like cells and predictor of
poor prognosis in esophageal squamous cell carcinoma. Hum. Pathol. 2018, 81, 148–156. [CrossRef] [PubMed]
33. Ogawa, T.; Hirohashi, Y.; Murai, A.; Nishidate, T.; Okita, K.; Wang, L.; Ikehara, Y.; Satoyoshi, T.; Usui, A.; Kubo, T.; et al.
ST6GALNAC1 plays important roles in enhancing cancer stem phenotypes of colorectal cancer via the Akt pathway. Oncotarget
2017, 8, 112550–112564. [CrossRef]
34. Xue, Z.; Yan, H.; Li, J.; Liang, S.; Cai, X.; Chen, X.; Wu, Q.; Gao, L.; Wu, K.; Nie, Y.; et al. Identification of cancer stem cells in
vincristine preconditioned SGC7901 gastric cancer cell line. J. Cell Biochem. 2012, 113, 302–312. [CrossRef] [PubMed]
35. Zhu, Z.; Xu, J.; Li, L.; Ye, W.; Xu, G.; Chen, B.; Zeng, J.; Li, J.; Huang, Z. Effect of gastric cancer stem cell on gastric cancer invasion,
migration and angiogenesis. Int. J. Med. Sci. 2020, 17, 2040–2051. [CrossRef]
36. Li, C.; Heidt, D.G.; Dalerba, P.; Burant, C.F.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M.F.; Simeone, D.M. Identification of
pancreatic cancer stem cells. Cancer Res. 2007, 67, 1030–1037. [CrossRef]
37. Hermann, P.C.; Huber, S.L.; Herrler, T.; Aicher, A.; Ellwart, J.W.; Guba, M.; Bruns, C.J.; Heeschen, C. Distinct populations of
cancer stem cells determine tumor growth and metastatic activity in human pancreatic Cancer. Cell Stem Cell. 2007, 1, 313–323.
[CrossRef] [PubMed]
38. Yamashita, T.; Wang, X.W. Cancer stem cells in the development of liver Cancer. J. Clin. Invest. 2013, 123, 1911–1918. [CrossRef]
[PubMed]
Cancers 2021, 13, 1239 25 of 31
39. Masciale, V.; Grisendi, G.; Banchelli, F.; D’Amico, R.; Maiorana, A.; Sighinolfi, P.; Stefani, A.; Morandi, U.; Dominici, M.; Aramini,
B. Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot
Study. Bd. 9. Front. Oncol. 2019, s, 1394. [CrossRef]
40. Herreros-Pomares, A.; De-Maya-Girones, J.D.; Calabuig-Fariñas, S.; Lucas, R.; Martínez, A.; Pardo-Sánchez, J.M.; Alonso, S.;
Blasco, A.; Guijarro, R.; Martorell, M.; et al. Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic
impact in resected non-small-cell lung. Cancer Cell Death Dis. 2019, 10, 660. [CrossRef] [PubMed]
41. Wang, J.; Sakariassen, P.Ø.; Tsinkalovsky, O.; Immervoll, H.; Bøe, S.O.; Svendsen, A.; Prestegarden, L.; Røsland, G.; Thorsen, F.;
Stuhr, L.; et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Cancer 2008, 122,
761–768. [CrossRef]
42. Bradshaw, A.; Wickremesekera, A.; Brasch, H.D.; Chibnall, A.M.; Davis, P.F.; Tan, S.T.; Itinteang, T. Cancer Stem Cells in
Glioblastoma Multiforme. Front. Surg. 2016, 348, 48. [CrossRef]
43. Basu-Roy, U.; Seo, E.; Ramanathapuram, L.; Rapp, T.B.; Perry, J.A.; Orkin, S.H.; Mansukhani, A.; Basilico, C. Sox2 maintains self
renewal of tumor-initiating cells in osteosarcomas. Oncogene 2012, 31, 2270–2282. [CrossRef] [PubMed]
44. Moreira, M.P.; da Conceição Braga, L.; Silva, L.M. STAT3 as a promising chemoresistance biomarker associated with the
CD44+/high/CD24-/low/ALDH+ BCSCs-like subset of the triple-negative breast cancer (TNBC) cell line. Exp. Cell Res. 2018,
363, 283–290. [CrossRef]
45. Golebiewska, A.; Brons, N.H.; Bjerkvig, R.; Niclou, S.P. Critical appraisal of the side population assay in stem cell and cancer stem
cell research. Cell Stem Cell. 2011, 8, 136–147. [CrossRef]
46. Murase, M.; Kano, M.; Tsukahara, T.; Takahashi, A.; Torigoe, T.; Kawaguchi, S.; Kimura, S.; Wada, T.; Uchihashi, Y.; Kondo, T.;
et al. Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br. J. Cancer
2009, 101, 1425–1432. [CrossRef] [PubMed]
47. Tomita, H.; Tanaka, K.; Tanaka, T.; Hara, A. Aldehyde dehydrogenase 1A1 in stem cells and Cancer. Oncotarget 2016, 7,
11018–11032. [CrossRef] [PubMed]
48. Xu, X.; Chai, S.; Wang, P.; Zhang, C.; Yang, Y.; Yang, Y.; Wang, K. Aldehyde dehydrogenases and cancer stem cells. Cancer Lett.
2015, 369, 50–57. [CrossRef]
49. Somervaille, T.C.; Cleary, M.L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid
leukemia. Cancer Cell. 2006, 10, 257–268. [CrossRef]
50. Liu, L.; Cheung, T.H.; Charville, G.W.; Hurgo, B.M.; Leavitt, T.; Shih, J.; Brunet, A.; Rando, T.A. Chromatin modifications as
determinants of muscle stem cell quiescence and chronological aging. Cell Rep. 2013, 4, 189–204. [CrossRef]
51. Sreepadmanabh, M.; Toley, B.J. Investigations into the cancer stem cell niche using in-vitro 3-D tumor models and microfluidics.
Biotechnol. Adv. 2018, 36, 1094–1110. [CrossRef]
52. LaBarbera, D.V.; Reid, B.G.; Yoo, B.H. The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert
Opin. Drug. Discov. 2012, 7, 819–883. [CrossRef]
53. Forde, S.; Matthews, J.D.; Jahangiri, L.; Lee, L.C.; Prokoph, N.; Malcolm, T.I.; Giger, O.T.; Bell, N.; Blair, H.; O’Marcaigh, A.; et al.
Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy. Br.
J. Haematol. 2021, 192, 354–365. [CrossRef]
54. Dalerba, P.; Cho, R.W.; Clarke, M.F. Cancer stem cells: Models and concepts. Annu. Rev. Med. 2007, 58, 267–284. [CrossRef]
[PubMed]
55. Islam, F.; Gopalan, V.; Wahab, R.; Smith, R.A.; Lam, A.K. Cancer stem cells in oesophageal squamous cell carcinoma: Identification,
prognostic and treatment perspectives. Crit. Rev. Oncol. Hematol. 2015, 96, 9–19. [CrossRef] [PubMed]
56. Tang, K.H.; Dai, Y.D.; Tong, M.; Chan, Y.P.; Kwanm, P.S.; Fu, L.; Qin, Y.R.; Tsao, S.W.; Lung, H.L.; Lung, M.L.; et al. A CD90(+)
tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal Cancer. Cancer Res. 2013, 73,
2322–2332. [CrossRef]
57. Liu, C.C.; Chou, K.T.; Hsu, J.W.; Lin, J.H.; Hsu, T.W.; Yen, D.H.; Hung, S.C.; Hsu, H.S. High metabolic rate and stem cell
characteristics of esophageal cancer stem-like cells depend on the Hsp27-AKT-HK2 pathway. Int. J. Cancer 2019, 145, 2144–2156.
[CrossRef]
58. Taniguchi, H.; Moriya, C.; Igarashi, H.; Saitoh, A.; Yamamoto, H.; Adachi, Y.; Imai, K. Cancer stem cells in human gastrointestinal
Cancer. Cancer Sci. 2016, 107, 1556–1562. [CrossRef]
59. Munro, M.J.; Wickremesekera, S.K.; Peng, L.; Tan, S.T.; Itinteang, T. Cancer stem cells in colorectal cancer: A review. J. Clin. Pathol.
2018, 71, 110–116. [CrossRef] [PubMed]
60. Ricci-Vitiani, L.; Lombardi, D.G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria, R. Identification and expansion of
human colon-cancer-initiating cells. Nature 2007, 445, 111–115. [CrossRef] [PubMed]
61. Clark, P.A.; Iida, M.; Treisman, D.M.; Kalluri, H.; Ezhilan, S.; Zorniak, M.; Wheeler, D.L.; Kuo, J.S. Activation of multiple ERBB
family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Neoplasia 2012, 14, 420–428.
[CrossRef]
62. Kang, T.W.; Choi, S.W.; Yang, S.R.; Shin, T.H.; Kim, H.S.; Yu, K.R.; Hong, I.S.; Ro, S.; Cho, J.M.; Kang, K.S. Growth arrest and
forced differentiation of human primary glioblastoma multiforme by a novel small molecule. Sci. Rep. 2014, 4, 5546. [CrossRef]
Cancers 2021, 13, 1239 26 of 31
63. Cheray, M.; Bessette, B.; Lacroix, A.; Mélin, C.; Jawhari, S.; Pinet, S.; Deluche, E.; Clavère, P.; Durand, K.; Sanchez-Prieto, R.; et al.
KLRC3, a Natural Killer receptor gene, is a key factor involved in glioblastoma tumourigenesis and aggressiveness. J. Cell Mol.
Med. 2017, 21, 244–253. [CrossRef]
64. Wang, H.H.; Liao, C.C.; Chow, N.H.; Huang, L.L.; Chuang, J.I.; Wei, K.C.; Shin, J.W. Whether CD44 is an applicable marker for
glioma stem cells. Am. J. Transl. Res. 2017, 9, 4785–4806. [PubMed]
65. Yang, M.; Yan, M.; Zhang, R.; Li, J.; Luo, Z. Side population cells isolated from human osteosarcoma are enriched with
tumor-initiating cells. Cancer Sci. 2011, 102, 1774. [CrossRef]
66. Maurizi, G.; Verma, N.; Gadi, A.; Mansukhani, A.; Basilico, C. Sox2 is required for tumor development and cancer cell proliferation
in osteosarcoma. Oncogene August 2018, 37, 4626–4632. [CrossRef] [PubMed]
67. Deter, R.L.; De Duve, C. Influence of glucagon, an inducer of cellular autophagy, on some physical properties of rat liver
lysosomes. J. Cell Biol. 1967, 33, 437–449. [CrossRef]
68. Wang, C.; Wang, X. The interplay between autophagy and the ubiquitin-proteasome system in cardiac proteotoxicity. Biochim.
Biophys. Acta 2015, 1852, 188–194. [CrossRef] [PubMed]
69. Lilienbaum, A. Relationship between the proteasomal system and autophagy. Int. J. Biochem. Mol. Biol. 2013, 4, 1–26. [PubMed]
70. Russell, R.C.; Yuan, H.X.; Guan, K.L. Autophagy regulation by nutrient signaling. Cell Res. 2014, 24, 42–57. [CrossRef]
71. Fulda, S.; Gorman, A.M.; Hori, O.; Samali, A. Cellular stress responses: Cell survival and cell death. Int. J. Cell Biol. 2010, 2010,
214074. [CrossRef] [PubMed]
72. Mari, M.; Tooze, S.A.; Reggiori, F. The puzzling origin of the autophagosomal membrane. F1000 Biol. Rep. 2011, 3, 25. [CrossRef]
[PubMed]
73. Klionsky, D.J.; Cuervo, A.M.; Seglen, P.O. Methods for monitoring autophagy from yeast to human. Autophagy 2007, 3, 181–206.
[CrossRef]
74. Tooze, S.A.; Yoshimori, T. The origin of the autophagosomal membrane. Nat. Cell Biol. 2010, 12, 831–835. [CrossRef] [PubMed]
75. Roberts, R.; Ktistakis, N.T. Omegasomes: PI3P platforms that manufacture autophagosomes. Essays Biochem. 2013, 55, 17–27.
[PubMed]
76. Esclatine, A.; Chaumorcel, M.; Codogno, P. Macroautophagy signaling and regulation. Curr. Top. Microbiol. Immunol. 2009, 335,
33–70. [PubMed]
77. Eskelinen, E.L.; Saftig, P. Autophagy: A lysosomal degradation pathway with a central role in health and disease. Biochim.
Biophys. Acta 2009, 1793, 664–673. [CrossRef] [PubMed]
78. Mizushima, N. Autophagy: Process and function. Genes Dev. 2007, 21, 2861–2873. [CrossRef] [PubMed]
79. Monastyrska, I.; Rieter, E.; Klionsky, D.J.; Reggiori, F. Multiple roles of the cytoskeleton in autophagy. Biol. Rev. Camb. Philos. Soc.
2009, 84, 431–448. [CrossRef] [PubMed]
80. Smith, A.G.; Macleod, K.F. Autophagy, cancer stem cells and drug resistance. J. Pathol. 2019, 247, 708–718. [CrossRef] [PubMed]
81. Praharaj, P.P.; Panigrahi, D.P.; Bhol, C.S.; Patra, S.; Mishra, S.R.; Mahapatra, K.K.; Behera, B.P.; Singh, A.; Patil, S.; Bhutia, S.K.
Mitochondrial rewiring through mitophagy and mitochondrial biogenesis in cancer stem cells: A potential target for anti-CSC
cancer therapy. Cancer Lett. 2021, 498, 217–228. [CrossRef] [PubMed]
82. Van Doeselaar, S.; Burgering, B.M.T. FOXOs Maintaining the Equilibrium for Better or for Worse. Curr. Top. Dev. Biol. 2018, 127,
49–103.
83. Barzilay, R.; Melamed, E.; Offen, D. Introducing Transcription Factors to Multipotent Mesenchymal Stem Cells: Making
Transdifferentiation Possible. Stem Cells 2009, 27, 2509–2515. [CrossRef] [PubMed]
84. Peng, Q.; Qin, J.; Zhang, Y.; Cheng, X.; Wang, X.; Lu, W.; Xie, X.; Zhang, S. Autophagy maintains the stemness of ovarian cancer
stem cells by FOXA2. J. Exp. Clin. Cancer Res. 2017, 36, 171. [CrossRef]
85. Cufí, S.; Vazquez-Martin, A.; Oliveras-Ferraros, C.; Martin-Castillo, B.; Vellon, L.; Menendez, J.A. Autophagy positively regulates
the CD44(+) CD24(-/low) breast cancer stem-like phenotype. Cell Cycle. 2011, 10, 3871–3885. [CrossRef]
86. Galavotti, S.; Bartesaghi, S.; Faccenda, D.; Shaked-Rabi, M.; Sanzone, S.; McEvoy, A.; Dinsdale, D.; Condorelli, F.; Brandner, S.;
Campanella, M.; et al. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma
stem cells. Oncogene 2013, 32, 699–712. [CrossRef]
87. Kiyono, K.; Suzuki, H.I.; Matsuyama, H.; Morishita, Y.; Komuro, A.; Kano, M.R.; Sugimoto, K.; Miyazono, K. Autophagy is
activated by TGF-beta and potentiates TGF-beta-mediated growth inhibition in human hepatocellular carcinoma cells. Cancer Res.
2009, 69, 8844–8852. [CrossRef]
88. Morel, A.P.; Lièvre, M.; Thomas, C.; Hinkal, G.; Ansieau, S.; Puisieux, A. Generation of breast cancer stem cells through
epithelial-mesenchymal transition. PLoS ONE 2008, 3, e2888. [CrossRef]
89. Courtois, S.; Haykal, M.; Bodineau, C.; Sifré, E.; Azzi-Martin, L.; Ménard, A.; Mégraud, F.; Lehours, P.; Durán, R.V.; Varon, C.;
et al. Autophagy induced by Helicobacter pylori infection is necessary for gastric cancer stem cell emergence. Gastric. Cancer
2021, 24, 133–144. [CrossRef] [PubMed]
90. Flynn, A.B.; Schiemann, W.P. Autophagy in breast cancer metastatic dormancy: Tumor suppressing or tumor promoting functions?
J. Cancer Metastasis Treat. 2019, 5, 43. [PubMed]
91. Chaterjee, M.; van Golen, K.L. Breast cancer stem cells survive periods of farnesyl-transferase inhibitor-induced dormancy by
undergoing autophagy. Bone Marrow Res. 2011, 2011, 362938. [CrossRef]
Cancers 2021, 13, 1239 27 of 31
92. Gong, C.; Bauvy, C.; Tonelli, G.; Yue, W.; Deloménie, C.; Nicolas, V.; Zhu, Y.; Domergue, V.; Marin-Esteban, V.; Tharinger, H.;
et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene 2013, 32,
2261–2272. [CrossRef]
93. Maycotte, P.; Jones, K.L.; Goodall, M.L.; Thorburn, J.; Thorburn, A. Autophagy Supports Breast Cancer Stem Cell Maintenance by
Regulating IL6 Secretion. Mol. Cancer Res. 2015, 13, 651–658. [CrossRef]
94. Ojha, R.; Bhattacharyya, S.; Singh, S.K. Autophagy in Cancer Stem Cells: A Potential Link Between Chemoresistance, Recurrence,
and Metastasis. Biores. Open Access. 2015, 4, 97–108. [CrossRef] [PubMed]
95. Mele, L.; del Vecchio, V.; Liccardo, D.; Prisco, C.; Schwerdtfeger, M.; Robinson, N.; Desiderio, V.; Tirino, V.; Papaccio, G.; La Noce,
M. The role of autophagy in resistance to targeted therapies. Cancer Treat Rev. 2020, 88, 102043. [CrossRef]
96. Golden, E.B.; Cho, H.Y.; Jahanian, A.; Hofman, F.M.; Louie, S.G.; Schönthal, A.H.; Chen, T.C. Chloroquine enhances temozolomide
cytotoxicity in malignant gliomas by blocking autophagy. Neurosurg. Focus. 2014, 37, E12. [CrossRef] [PubMed]
97. Li, L.-Q.; Pan, D.; Zhang, S.-W.; Xie, D.-Y.; Zheng, X.-L.; Chen, H. Autophagy regulates chemoresistance of gastric cancer stem
cells via the Notch signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 3402–3407.
98. Fu, Y.; Chang, H.; Peng, X.; Bai, Q.; Yi, L.; Zhou, Y.; Zhu, J.; Mi, M. Resveratrol inhibits breast cancer stem-like cells and induces
autophagy via suppressing Wnt/β-catenin signaling pathway. PLoS ONE 2014, 9, e102535. [CrossRef]
99. Rahman, M.A.; Saha, S.K.; Rahman, M.S.; Uddin, M.J.; Uddin, M.S.; Pang, M.-G.; Rhim, H.; Cho, S.G. Molecular Insights Into
Therapeutic Potential of Autophagy Modulation by Natural Products for Cancer Stem Cells. Front. Cell Dev. Biol. 2020, 8, 283.
[CrossRef]
100. Mandhair, H.K.; Arambasic, M.; Novak, U.; Radpour, R. Molecular modulation of autophagy: New venture to target resistant
cancer stem cells. World J. Stem Cells. 2020, 12, 303–322. [CrossRef] [PubMed]
101. Baquero, P.; Dawson, A.; Mukhopadhyay, A.; Kuntz, E.M.; Mitchell, R.; Olivares, O.; Ianniciello, A.; Scott, M.T.; Dunn, K.; Nicastri,
M.C.; et al. Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. Leukemia 2019, 33, 981–994.
[CrossRef]
102. Terry, S.; Faouzi Zaarour, R.; Hassan Venkatesh, G.; Francis, A.; El-Sayed, W.; Buart, S.; Bravo, P.; Thiery, J.; Chouaib, S. Role
of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity. Int. J. Mol. Sci. 2018, 19, 3044. [CrossRef]
[PubMed]
103. Tong, W.; Tong, G.; Liu, Y. Cancer stem cells and hypoxia-inducible factors (Review). Int. J. Oncol. 2018, 53, 469–476. [CrossRef]
[PubMed]
104. Semenza, G.L. Dynamic regulation of stem cell specification and maintenance by hypoxia-inducible factors. Mol. Aspects Med.
2016, 47, 15–23. [CrossRef] [PubMed]
105. Yang, M.; Wu, M.; Chiou, S.; Chen, P.; Chang, S.; Liu, C.; Teng, S.; Wu, K. Direct regulation of TWIST by HIF-1α promotes
metastasis. Nat. Cell Biol. 2008, 10, 295–305. [CrossRef] [PubMed]
106. Nakuluri, K.; Mukhi, D.; Nishad, R.; Saleem, M.A.; Mungamuri, S.K.; Menon, R.K.; Pasupulati, A.K. Hypoxia induces ZEB2 in
podocytes: Implications in the pathogenesis of proteinuria. J. Cell Physiol. 2019, 234, 6503–6518. [CrossRef]
107. Xu, X.; Tan, X.; Tampe, B.; Sanchez, E.; Zeisberg, M.; Zeisberg, E.M. ducible Factor 1α (HIF1α) in Hypoxia-induced Endothelial to
Mesenchymal Transition of Human Coronary Endothelial Cells. J. Biol. Chem. 2015, 290, 16653–16664. [CrossRef] [PubMed]
108. Bellot, G.; Garcia-Medina, R.; Gounon, P.; Chiche, J.; Roux, D.; Pouysségur, J.; Mazure, N.M. Hypoxia-Induced Autophagy Is
Mediated through Hypoxia-Inducible Factor Induction of BNIP3 and BNIP3L via Their BH3 Domains. Mol. Cell Biol. 2009, 29,
2570–2581. [CrossRef]
109. Hasmim, M.; Janji, B.; Khaled, M.; Noman, M.Z.; Louache, F.; Bordereaux, D.; Abderamane, A.; Baud, V.; Mami-Chouaib, F.;
Chouaib, S. Cutting Edge: NANOG Activates Autophagy under Hypoxic Stress by Binding to BNIP3L Promoter. J. Immunol.
2017, 198, 1423–1428. [CrossRef] [PubMed]
110. Zhu, H.; Wang, D.; Liu, Y.; Su, Z.; Zhang, L.; Chen, F.; Zhou, Y.; Wu, Y.; Yu, M.; Zhang, Z.; et al. Role of the Hypoxia-inducible
factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like
cells. Cancer Cell Int. 2013, 13, 119. [CrossRef]
111. Qureshi-Baig, K.; Kuhn, D.; Viry, E.; Pozdeev, V.I.; Schmitz, M.; Rodriguez, F.; Ullmann, P.; Koncina, E.; Nurmik, M.; Frasquilho,
S.; et al. Hypoxia-induced autophagy drives colorectal cancer initiation and progression by activating the PRKC/PKC-EZR
(ezrin) pathway. Autophagy 2020, 16, 1436–1452. [CrossRef]
112. Yuan, N.; Song, L.; Zhang, S.; Lin, W.; Cao, Y.; Xu, F.; Fang, Y.; Wang, Z.; Zhang, H.; Li, X.; et al. Bafilomycin A1 targets both
autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica 2015, 100, 345–356. [CrossRef]
113. Wouters, B.; Koritzinsky, M. Hypoxia signalling through mTOR and the unfolded protein response in Cancer. Nat. Rev. Cancer
2008, 8, 851–864. [CrossRef]
114. Land, S.C.; Tee, A.R. Hypoxia-inducible Factor 1α Is Regulated by the Mammalian Target of Rapamycin (mTOR) via an mTOR
Signaling Motif. J. Biol. Chem. 2007, 282, 20534–20543. [CrossRef] [PubMed]
115. Agani, F.; Jiang, B.H. Oxygen-independent Regulation of HIF-1: Novel Involvement of PI3K/ AKT/mTOR Pathway in Cancer
Bd. 13. Curr. Cancer Drug Targets 2013, 3, 245–251. [CrossRef]
116. Losuwannarak, N.; Maiuthed, A.; Kitkumthorn, N.; Leelahavanichkul, A.; Roytrakul, S.; Chanvorachote, P. Gigantol Targets
Cancer Stem Cells and Destabilizes Tumors via the Suppression of the PI3K/AKT and JAK/STAT Pathways in Ectopic Lung
Cancer Xenografts. Cancers 2019, 11, 2032. [CrossRef] [PubMed]
Cancers 2021, 13, 1239 28 of 31
117. Li, X.; Liu, X.; Xu, Y.; Liu, J.; Xie, M.; Ni, W.; Chen, S. KLF5 promotes hypoxia-induced survival and inhibits apoptosis in non-small
cell lung cancer cells via HIF-1α. Int. J. Oncol. 2014, 45, 1507–1514. [CrossRef] [PubMed]
118. Gong, T.; Cui, L.; Wang, H.; Wang, H.; Han, N. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC
cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway. J. Transl. Med. 2018, 16,
164. [CrossRef]
119. Nazio, F.; Bordi, M.; Cianfanelli, F.; Cecconi, F. Autophagy and cancer stem cells: Molecular mechanisms and therapeutic
applications. Cell Death Differ. 2019, 26, 690–702. [CrossRef]
120. Ding, W.X.; Yin, X.M. Mitophagy: Mechanisms, pathophysiological roles, and analysis. Biol. Chem. 2012, 393, 547–564. [CrossRef]
121. Pickles, S.; Vigié, P.; Youle, R.J. Mitophagy and Quality Control Mechanisms in Mitochondrial Maintenance. Curr. Biol. 2018, 28,
R170–R185. [CrossRef] [PubMed]
122. Jin, S.M.; Youle, R.J. PINK1- and Parkin-mediated mitophagy at a glance. J. Cell Sci. 2012, 125, 795–799. [CrossRef] [PubMed]
123. Peiris-Pagès, M.; Martinez-Outschoorn, U.E.; Pestell, R.G.; Sotgia, F.; Lisanti, M.P. Cancer stem cell metabolism. Breast Cancer Res.
2016, 18, 55. [CrossRef]
124. Peixoto, J.; Lima, J. Metabolic traits of cancer stem cells. Dis. Model. Mech. 2018, 11, dmm033464. [CrossRef]
125. Lleonart, M.E.; Abad, E.; Graifer, D.; Lyakhovich, A. Reactive Oxygen Species-Mediated Autophagy Defines the Fate of Cancer
Stem Cells. Antioxid. Redox Signal. 2018, 28, 1066–1079. [CrossRef] [PubMed]
126. Held, N.M.; Houtkooper, R.H. Mitochondrial quality control pathways as determinants of metabolic health. Bioessays 2015, 37,
867–876. [CrossRef]
127. Tanaka, A.; Cleland, M.M.; Xu, S.; Narendra, D.P.; Suen, D.F.; Karbowski, M.; Youle, R.J. Proteasome and p97 mediate mitophagy
and degradation of mitofusins induced by Parkin. J. Cell Biol. 2010, 191, 1367–1380. [CrossRef]
128. Rambold, A.S.; Kostelecky, B.; Elia, N.; Lippincott-Schwartz, J. Tubular network formation protects mitochondria from autophago-
somal degradation during nutrient starvation. PNAS 2011, 108, 10190–10195. [CrossRef] [PubMed]
129. Xie, Q.; Wu, Q.; Horbinski, C.M.; Flavahan, W.A.; Yang, K.; Zhou, W.; Dombrowski, S.M.; Huang, Z.; Fang, X.; Shi, Y.; et al.
Mitochondrial control by DRP1 in brain tumor initiating cells. Nat. Neurosci. 2015, 18, 501–510. [CrossRef]
130. Liu, K.; Lee, J.; Kim, J.Y.; Wang, L.; Tian, Y.; Chan, S.T.; Cho, C.; Machida, K.; Chen, D.; Ou, J.J. Mitophagy Controls the Activities
of Tumor Suppressor p53 to Regulate Hepatic Cancer Stem Cells. Mol. Cell. 2017, 68, 281–292. [CrossRef] [PubMed]
131. Yan, C.; Luo, L.; Guo, C.-Y.; Goto, S.; Urata, Y.; Shao, J.-H.; Li, T.-S. Doxorubicin-induced mitophagy contributes to drug resistance
in cancer stem cells from HCT8 human colorectal cancer cells. Cancer Lett. 2017, 388, 34–42. [CrossRef]
132. Yan, C.; Li, T.S. Dual Role of Mitophagy in Cancer Drug Resistance. Anticancer Res. 2018, 38, 617–621. [PubMed]
133. Zhou, J.; Li, G.; Zheng, Y.; Shen, H.M.; Hu, X.; Ming, Q.L.; Huang, C.; Li, P.; Gao, N. A novel autophagy/mitophagy inhibitor
liensinine sensitizes breast cancer cells to chemotherapy through DNM1L-mediated mitochondrial fission. Autophagy 2015, 11,
1259–1279. [CrossRef]
134. Pennisi, E. Genomics. ENCODE project writes eulogy for junk DNA. Science 2012, 337, 1159–1161. [CrossRef] [PubMed]
135. Ponjavic, J.; Ponting, C.P.; Lunter, G. Functionality or transcriptional noise? Evidence for selection within long noncoding RNAs.
Genome Res. 2007, 17, 556–565. [CrossRef] [PubMed]
136. Xu, Z.; Liu, C.; Zhao, Q.; Lü, J.; Ding, X.; Luo, A.; He, J.; Wang, G.; Li, Y.; Cai, Z.; et al. Long non-coding RNA CCAT2 promotes
oncogenesis in triple-negative breast cancer by regulating stemness of cancer cells. Pharmacol. Res. 2020, 152, 104628. [CrossRef]
137. Wu, J.; Zhu, P.; Lu, T.; Du, Y.; Wang, Y.; He, L.; Ye, B.; Liu, B.; Yang, L.; Wang, J.; et al. The long non-coding RNA LncHDAC2
drives the self-renewal of liver cancer stem cells via activation of Hedgehog signaling. J. Hepatol. 2019, 70, 918–929. [CrossRef]
138. Crea, F.; Clermont, P.L.; Parolia, A.; Wang, Y.; Helgason, C.D. The non-coding transcriptome as a dynamic regulator of cancer
metastasis. Cancer Metastasis Rev. 2014, 33, 1–16. [CrossRef] [PubMed]
139. Crea, F.; Venalainen, E.; Ci, X.; Cheng, H.; Pikor, L.; Parolia, A.; Xue, H.; Nur Saidy, N.R.; Lin, D.; Lam, W.; et al. The role
of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate. Cancer Epigenomics 2016, 8, 721–731. [CrossRef]
[PubMed]
140. Jiao, F.; Hu, H.; Han, T.; Yuan, C.; Wang, L.; Jin, Z.; Guo, Z.; Wang, L. Long noncoding RNA MALAT-1 enhances stem cell-like
phenotypes in pancreatic cancer cells. Int. J. Mol. Sci. 2015, 16, 6677–6693. [CrossRef] [PubMed]
141. Peperstraete, E.; Lecerf, C.; Collette, J.; Vennin, C.; Raby, L.; Völkel, P.; Angrand, P.O.; Winter, M.; Bertucci, F.; Finetti, P.; et al.
Enhancement of Breast Cancer Cell Aggressiveness by lncRNA H19 and its Mir-675 Derivative: Insight into Shared and Different
Actions. Cancers 2020, 29, 1730. [CrossRef]
142. Dai, D.; Wang, H.; Zhu, L.; Jin, H.; Wang, X. N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis.
2018, 9, 124. [CrossRef]
143. Siebenthall, K.T.; Miller, C.P.; Vierstra, J.D.; Mathieu, J.; Tretiakova, M.; Reynolds, A.; Sandstrom, R.; Rynes, E.; Haugen, E.;
Johnson, A.; et al. Integrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma. EBioMedicine
2019, 41, 427–442. [CrossRef] [PubMed]
144. Yan, H.; Bu, P. Non-coding RNAs in cancer stem cells. Cancer Lett. 2018, 421, 121–126. [CrossRef]
145. Huang, R.; Zhu, L.; Zhang, Y. XIST lost induces ovarian cancer stem cells to acquire taxol resistance via a KMT2C-dependent way.
Cancer Cell Int. 2020, 20, 436. [CrossRef] [PubMed]
Cancers 2021, 13, 1239 29 of 31
146. Zheng, Q.; Xu, J.; Lin, Z.; Lu, Y.; Xin, X.; Li, X.; Yang, Y.; Meng, Q.; Wang, C.; Xiong, W.; et al. Inflammatory factor receptor
Toll-like receptor 4 controls telomeres through heterochromatin protein 1 isoforms in liver cancer stem cell. J. Cell Mol. Med. 2018,
22, 3246–3258. [CrossRef] [PubMed]
147. Li, H.; An, J.; Wu, M.; Zheng, Q.; Gui, X.; Li, T.; Pu, H.; Lu, D. LncRNA HOTAIR promotes human liver cancer stem cell malignant
growth through downregulation of SETD2. Oncotarget 2015, 6, 27847–27864. [CrossRef]
148. Li, L.; Dang, Q.; Xie, H.; Yang, Z.; He, D.; Liang, L.; Song, W.; Yeh, S.; Chang, C. Correction: Infiltrating mast cells enhance prostate
cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell
population. Oncotarget 2016, 7, 83828. [CrossRef]
149. Sasaki, N.; Toyoda, M.; Yoshimura, H.; Matsuda, Y.; Arai, T.; Takubo, K.; Aida, J.; Ishiwata, T. H19 long non-coding RNA
contributes to sphere formation and invasion through regulation of CD24 and integrin expression in pancreatic cancer cells.
Oncotarget 2018, 9, 34719–34734. [CrossRef] [PubMed]
150. Shima, H.; Kida, K.; Adachi, S.; Yamada, A.; Sugae, S.; Narui, K.; Miyagi, Y.; Nishi, M.; Ryo, A.; Murata, S.; et al. Lnc RNA H19
is associated with poor prognosis in breast cancer patients and promotes cancer stemness. Breast Cancer Res. Treat. 2018, 170,
507–516. [CrossRef]
151. Zhan, Y.; Chen, Z.; He, S.; Gong, Y.; He, A.; Li, Y.; Zhang, L.; Zhang, X.; Fang, D.; Li, X.; et al. Long non-coding RNA SOX2OT
promotes the stemness phenotype of bladder cancer cells by modulating SOX2. Mol. Cancer 2020, 19, 25. [CrossRef]
152. Zheng, A.; Song, X.; Zhang, L.; Zhao, L.; Mao, X.; Wei, M.; Jin, F. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis
regulates breast cancer stemness via Wnt/β-catenin pathway. J. Exp. Clin. Cancer Res. 2019, 38, 305. [CrossRef] [PubMed]
153. Pucci, P.; Rescigno, P.; Sumanasuriya, S.; de Bono, J.; Crea, F. Hypoxia and Noncoding RNAs in Taxane Resistance. Trends
Pharmacol. Sci. 2018, 39, 695–709. [CrossRef]
154. Wang, X.; Sun, W.; Shen, W.; Xia, M.; Chen, C.; Xiang, D.; Ning, B.; Cui, X.; Li, H.; Li, X.; et al. Long non-coding RNA DILC
regulates liver cancer stem cells via IL-6/STAT3 axis. J. Hepatol. 2016, 64, 1283–1294. [CrossRef] [PubMed]
155. Huang, R.; Nie, W.; Yao, K.; Chou, J. Depletion of the lncRNA RP11-567G11.1 inhibits pancreatic cancer progression. Biomed.
Pharmacother. 2019, 112, 108685. [CrossRef] [PubMed]
156. Pucci, P.; Venalainen, E.; Alborelli, I.; Quagliata, L.; Hawkes, C.; Mather, R.; Romero, I.; Rigas, S.H.; Wang, Y.; Crea, F. LncRNA
HORAS5 promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism. Epigenomics
2020, 12, 1123–1138. [CrossRef]
157. Qiu, G.; Ma, D.; Li, F.; Sun, D.; Zeng, Z. lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated
with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in
cholangiocarcinoma. Int. J. Oncol. 2019, 55, 45–58. [CrossRef] [PubMed]
158. Bellmunt, J.; Eigl, B.J.; Senkus, E.; Loriot, Y.; Twardowski, P.; Castellano, D.; Blais, N.; Sridhar, S.S.; Sternberg, C.N.; Retz, M.; et al.
Borealis-1: A randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with
advanced urothelial Cancer. Ann. Oncol. 2017, 28, 2481–2488. [CrossRef] [PubMed]
159. Chi, K.N.; Higano, C.S.; Blumenstein, B.; Ferrero, J.M.; Reeves, J.; Feyerabend, S.; Gravis, G.; Merseburger, A.S.; Stenzl, A.;
Bergman, A.M.; et al. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant
prostate cancer (SYNERGY trial): A phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2017, 18, 473–485. [CrossRef]
160. Chery, J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J. 2016, 4, 35–50. [CrossRef]
161. Liang, X.H.; Sun, H.; Nichols, J.G.; Crooke, S.T. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in
Directing RNA Cleavage in Both the Cytoplasm and the Nucleus. Mol. Ther. 2017, 25, 2075–2092. [CrossRef]
162. Wang, W.T.; Han, C.; Sun, Y.M.; Chen, T.Q.; Chen, Y.Q. Noncoding RNAs in cancer therapy resistance and targeted drug
development. J. Hematol. Oncol. 2019, 12, 55. [CrossRef] [PubMed]
163. Shen, X.; Corey, D.R. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res.
2018, 46, 1584–1600. [CrossRef] [PubMed]
164. Sekhon, H.S.; London, C.A.; Sekhon, M.; Iversen, P.L.; Devi, G.R. c-MYC antisense phosphosphorodiamidate morpholino
oligomer inhibits lung metastasis in a murine tumor model. Lung Cancer 2008, 60, 347–354. [CrossRef]
165. Iversen, P.L.; Arora, V.; Acker, A.J.; Mason, D.H.; Devi, G.R. Efficacy of antisense morpholino oligomer targeted to c-myc in
prostate cancer xenograft murine model and a Phase I safety study in humans. Clin. Cancer Res. 2003, 9, 2510–2519.
166. Vidovic, D.; Huynh, T.T.; Konda, P.; Dean, C.; Cruickshank, B.M.; Sultan, M.; Coyle, K.M.; Gujar, S.; Marcato, P. ALDH1A3-
regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells. Cell
Death Differ. 2020, 27, 363–378. [CrossRef] [PubMed]
167. Zhang, B.; Lu, H.Y.; Xia, Y.H.; Jiang, A.G.; Lv, Y.X. Long non-coding RNA EPIC1 promotes human lung cancer cell growth.
Biochem. Biophys. Res. Commun. 2018, 503, 1342–1348. [CrossRef]
168. Panda, S.; Setia, M.; Kaur, N.; Shepal, V.; Arora, V.; Singh, D.K.; Mondal, A.; Teli, A.; Tathode, M.; Gajula, R.; et al. Noncoding
RNA Ginir functions as an oncogene by associating with centrosomal proteins. PLoS Biol. 2018, 16, e2004204. [CrossRef]
169. Lavalou, P.; Eckert, H.; Damy, L.; Constanty, F.; Majello, S.; Bitetti, A.; Graindorge, A.; Shkumatava, A. Corrigendum: Strategies
for genetic inactivation of long noncoding RNAs in zebrafish. RNA 2020, 26, 529. [CrossRef]
170. Roobol, M.J.; Schröder, F.H.; van Leeuwen, P.; Wolters, T.; van den Bergh, R.C.; van Leenders, G.J.; Hessels, D. Performance of
the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: Exploring the value of PCA3 for a
first-line diagnostic test. Eur. Urol. 2010, 58, 475–481. [CrossRef] [PubMed]
Cancers 2021, 13, 1239 30 of 31
171. Sun, L.; Su, Y.; Liu, X.; Xu, M.; Chen, X.; Zhu, Y.; Guo, Z.; Bai, T.; Dong, L.; Wei, C.; et al. Serum and exosome long non coding
RNAs as potential biomarkers for hepatocellular carcinoma. J. Cancer 2018, 9, 2631–2639. [CrossRef]
172. Conigliaro, A.; Costa, V.; Lo Dico, A.; Saieva, L.; Buccheri, S.; Dieli, F.; Manno, M.; Raccosta, S.; Mancone, C.; Tripodi, M.; et al.
CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19, l.n.c.R.N.A. Mol.
Cancer 2015, 14, 155. [CrossRef] [PubMed]
173. Fu, Z.; Chen, C.; Zhou, Q.; Wang, Y.; Zhao, Y.; Zhao, X.; Li, W.; Zheng, S.; Ye, H.; Wang, L.; et al. LncRNA HOTTIP modulates
cancer stem cell properties in human pancreatic cancer by regulating HOXA9. Cancer Lett. 2017, 410, 68–81. [CrossRef]
174. Han, M.; Gu, Y.; Lu, P.; Li, J.; Cao, H.; Li, X.; Qian, X.; Yu, C.; Yang, Y.; Yang, X.; et al. Exosome-mediated lncRNA AFAP1-AS1
promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation. Mol. Cancer 2020, 19, 26.
[CrossRef] [PubMed]
175. Zhu, Z.; Wang, H.; Pang, Y.; Hu, H.; Zhang, H.; Wang, W. Exosomal long non-coding RNA UCA1 functions as growth inhibitor in
esophageal Cancer. Aging 2020, 12, 20523–20539. [CrossRef] [PubMed]
176. Wu, G.; Dawson, E.; Duong, A.; Haw, R.; Stein, L. ReactomeFIViz: A Cytoscape app for pathway and network-based data analysis.
F1000Research 2014, 3, 146.
177. Jassal, B.; Matthews, L.; Viteri, G.; Gong, C.; Lorente, P.; Fabregat, A.; Sidiropoulos, K.; Cook, J.; Gillespie, M.; Haw, R.; et al. The
reactome pathway knowledgebase. Nucleic Acids Res. 2020, 48, D498–D503. [CrossRef] [PubMed]
178. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A
software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13, 2498–2504. [CrossRef]
179. Szklarczyk, D.; Gable, A.L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva, N.T.; Morris, J.H.;
Bork, P.; et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in
genome-wide experimental datasets. Nucleic Acids Res. 2019, 47, D607–D613. [CrossRef]
180. Piñero, J.; Ramírez-Anguita, J.M. Saüch-Pitarch J, Ronzano F, Centeno E, Sanz F, Furlong LI. The DisGeNET knowledge platform
for disease genomics: 2019 update. Nucleic Acids Res. 2019, 48, D845–D885.
181. Yu, G.; Wang, L.-G.; Han, Y.; He, Q.-Y. ClusterProfiler: An R package for comparing biological themes among gene clusters. OMI
J. Integr. Biol. 2012, 16, 284–287. [CrossRef] [PubMed]
182. Montojo, J.; Zuberi, K.; Rodriguez, H.; Kazi, F.; Wright, G.; Donaldson, S.L.; Morris, Q.; Bader, G.D. GeneMANIA Cytoscape
plugin: Fast gene function predictions on the desktop. Bioinformatics 2010, 26, 2927–2928. [CrossRef]
183. Merico, D.; Isserlin, R.; Stueker, O.; Emili, A.; Bader, G.D. Enrichment Map: A Network-Based Method for Gene-Set Enrichment
Visualization and Interpretation. PLoS ONE 2010, 5, e13984. [CrossRef]
184. Terry, S.; Buart, S.; Tan, T.Z.; Gros, G.; Noman, M.Z.; Lorens, J.B.; Mami-Chouaib, F.; Thiery, J.P.; Chouaib, S. Acquisitionoftumor
cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated
cytotoxicity. Oncoimmunology 2017, 6, e1271858. [CrossRef]
185. Shi, J.; Dong, B.; Cao, J.; Mao, Y.; Guan, W.; Peng, Y.; Wang, S. Long non-coding RNA in glioma: Signaling pathways. Oncotarget
2017, 8, 27582–27592. [CrossRef]
186. Wang, S.S.; Jiang, J.; Liang, X.H.; Tang, Y.L. Links between cancer stem cells and epithelial-mesenchymal transition. Onco. Targets
Ther. 2015, 8, 2973–2980. [PubMed]
187. Galoczova, M.; Coates, P.; Vojtesek, B. STAT3, stem cells, cancer stem cells and p63. Cell Mol. Biol. Lett. 2018, 23, 12. [CrossRef]
[PubMed]
188. Yan, C.; Zhao, J.; Qin, Y.; Zhao, F.; Ji, L.; Zhang, J. Overexpression of ATG4a promotes autophagy and proliferation, and inhibits
apoptosis in lens epithelial cells via the AMPK and Akt pathways. Mol. Med. Rep. 2020, 22, 1295–1302. [CrossRef]
189. Martinez-Outschoorn, U.E.; Whitaker-Menezes, D.; Lin, Z.; Flomenberg, N.; Howell, A.; Pestell, R.G.; Lisanti, M.P.; Sotgia, F.
Cytokine production and inflammation drive autophagy in the tumor microenvironment: Role of stromal caveolin-1 as a key
regulator. Cell Cycle. 2011, 10, 1784–1793. [CrossRef] [PubMed]
190. Visvader, J.E. Cells of origin in Cancer. Nature 2011, 469, 314–322. [CrossRef]
191. Taussig, D.C.; Miraki-Moud, F.; Anjos-Afonso, F.; Pearce, D.J.; Allen, K.; Ridler, C.; Lillington, D.; Oakervee, H.; Cavenagh, J.;
Agrawal, S.G. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating
cells. Blood 2008, 112, 568–575. [CrossRef] [PubMed]
192. Jang, J.E.; Eom, J.I.; Jeung, H.K.; Cheong, J.W.; Lee, J.Y.; Kim, J.S.; Min, Y.H. Targeting AMPK-ULK1-mediated autophagy for
combating BET inhibitor resistance in acute myeloid leukemia stem cells. Autophagy 2017, 13, 761–762. [CrossRef] [PubMed]
193. Zhang, B.; Nguyen, L.X.T.; Li, L.; Zhao, D.; Kumar, B.; Wu, H.; Lin, A.; Pellicano, F.; Hopcroft, L.; Su, Y.-L.; et al. Bone marrow
niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat. Med. 2018,
24, 450–462. [CrossRef]
194. Silvestri, G.; Trotta, R.; Stramucci, L.; Ellis, J.J.; Harb, J.G.; Neviani, P.; Wang, S.; Eisfeld, A.K.; Walker, C.J.; Zhang, B.; et al.
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300
Antiproliferative and PP2A-Activating Functions. Blood. Cancer Discov. 2020, 1, 48–67. [CrossRef]
195. Wang, L.; Bu, P.; Ai, Y.; Srinivasan, T.; Chen, H.J.; Xiang, K.; Lipkin, S.M.; Shen, X. A long non-coding RNA targets microRNA
miR-34a to regulate colon cancer stem cell asymmetric division. Elife 2016, 5, e14620. [CrossRef] [PubMed]
196. Li, H.; Zhu, L.; Xu, L.; Qin, K.; Liu, C.; Yu, Y.; Su, D.; Wu, K.; Sheng, Y. Long noncoding RNA linc00617 exhibits oncogenic activity
in breast Cancer. Mol. Carcinog. 2017, 56, 3–17. [CrossRef] [PubMed]
Cancers 2021, 13, 1239 31 of 31
197. Meacham, C.E.; Morrison, S.J. Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501, 328–337. [CrossRef]
198. Notta, F.; Mullighan, C.G.; Wang, J.C.; Poeppl, A.; Doulatov, S.; Phillips, L.A.; Ma, J.; Minden, M.D.; Downing, J.R.; Dick, J.E.
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011, 469, 362–367. [CrossRef]
